WORLD’S CLINICAL NEWS LEADER
Vol.42 No.1 • 2-3/2024 ISSN 0898-7270
I N
Wearable Ultrasound
Predicts Liver Failure
H uman body tissues and or-
gans naturally stiffen with
age, and this process can be more
pronounced in certain diseases,
indicating a potential decline in
health. Clinicians currently use
ultrasound elastography to mea-
sure organ stiffness. This tech-
Cont’d on page 10
Novel Imaging Technique
Could Revolutionize Pancreatic
Cancer Surgery
A groundbreaking imag-
ing platform called Mul-
tispectral Optoacoustic To-
mography (MSOT) can now
enhance the detection of
pancreatic cancer cells at
the microscopic level, po-
tentially improving surgery
outcomes and extending
patient survival.
See article on Page 2
V I S
LINKXPRESS COM
I T
R E A D E R S E R V I C E P O R T A L
Renew/Start your
Free Subscription
Access Interactive
Digital Magazine
Instant Online
Product Information:
Identify LinkXpress codes of
1 interest
®
as you read magazine
on LinkXpress.com
2 toClick
reach reader service portal
Mark code(s) of interest on
3 LinkXpress inquiry matrix
®
If your subscription
is not renewed every 12 months
your Free Subscription may be
automatically discontinued
T E R N A T
AI Algorithm Monitors Vital Signs
to Detect Sepsis Before Symptoms
S epsis, a serious blood infec-
tion, can initiate a life-threat-
ening chain reaction throughout
the body and poses a significant
global health challenge. As a dys-
regulated host response to in-
fection, sepsis affects over 48.9
million people annually world-
3 mm
®
IVUS Improves Outcomes
in Cardiovascular Stenting
I
ntroduced over three decades
ago, intravascular ultrasound
(IVUS) offers a more precise and
detailed view of the coronary arter-
ies. Studies have demonstrated that
IVUS-guided percutaneous coronary
intervention (PCI) is more effective
than angiography-guided PCI in re-
Cont’d on page 4
International Hospital Federation
Announces 2023 IHF Award Winners
T he International Hospital Fed-
eration (IHF; Geneva, Swit-
zerland; www.ihf-fih.org) held its
annual Award Ceremony and Gala
Dinner on October 26, 2023, to
celebrate excellence in hospital and
healthcare leadership. The Awards
Ceremony was the highlight of
I O
wide, resulting in approximately
11 million deaths. Early detection
of sepsis is crucial for effective
treatment, including fluid resusci-
tation, antibiotic administration,
and source control. However,
identifying sepsis can be difficult
due to its heterogeneous nature.
Cont’d on page 15
200μm
Image courtesy of
University of Oklahoma
the 46th World Hospital Congress,
which saw 1500 attendees from
over 80 countries and territories.
The ceremony was held in Lisbon
(Portugal) at the Lisbon Congress
Centre in front of an audience com-
prising 500 international hospitals
and healthcare executives.
Cont’d on page 21
®
N A L
Catheter Prevents
Bacterial Infections
B acteria have developed ef-
ficient swimming abilities,
which can pose significant health
risks, particularly in medical set-
tings where catheters are com-
monly used. These thin tubes,
meant to remove fluids from the
body, can unfortunately serve as
pathways for bacteria to enter
and cause urinary tract infections,
leading to substantial healthcare
costs worldwide. In response, re-
Cont’d on page 12
Identifying Higher
Risk of TB Infection
T uberculosis (TB) is a serious
bacterial disease that primar-
ily affects the lungs and can be
deadly if left untreated. It spreads
through the air when people with
TB expel bacteria via droplets.
While many individuals who con-
tract TB remain asymptomatic, a
small percentage do not control
the infection, leading to active
disease. Current TB testing meth-
ods, such as skin tests or blood
tests like the interferon gamma
Cont’d on page 9
INSIDE
News Update . . . . . . . . . . 5
HospiMedica EXPO. . . 6-10
News Update . . . . . . . . . 11
HospiMedica EXPO . . 12-16
News Update . . . . . . . . . 17
HospiMedica EXPO. . 18-20
Industry News . . . . . . . . . . 21
International Calendar . . . 22
GLOBETECH
>>> MEDIA <<<
HospiMedica
To view this issue in interactive digital magazine format visit www.HospiMedica.com
International

Novel Imaging Technique Could

Revolutionize Pancreatic Cancer Surgery

P
ancreatic cancer, known for being particularly challenging to cure,
often goes undetected at the microscopic level due to typically
absent early symptoms. This often leads to late diagnosis when the
cancer has already spread, resulting in dire survival rates — approximately a
9% overall chance. The best chances for patient survival currently hinge on
surgery and chemotherapy, with the effectiveness of surgery dependent on
the complete removal of the cancer, a task complicated by the limitations
of current imaging techniques like CT scans, which only detect cancer
at a more advanced stage. A groundbreaking imaging approach can now
enhance the detection of pancreatic cancer cells at the microscopic level,
around 200 microns in size, similar to the thickness of an eyelash, potential-
ly improving surgery outcomes and extending patient survival.
At OU Health Stephenson Cancer Center at the University of Okla-
homa (Norman, OK, USA; www.ou.edu), researchers have launched
an innovative study combining a novel contrast agent, specifically de-
signed to target pancreatic cancer cells, with Multispectral Optoacoustic
Tomography (MSOT). This approach promises to detect cancer cells at
a magnitude approximately 10 times smaller than current capabilities. Image: Using MSOT to image the carotid artery (Courtesy of OMIG).
In the lab, the team developed a unique
contrast agent that reacts specifically to the
acidic environment of pancreatic cancer
cells. Delivered intravenously, this agent
can distinguish pancreatic cancer cells from

For small and medium labs,

@SINGUWAY is your answer.
≤30 minutes
Singu20 Nucleic Acid Extractor AccuRa-32 Real-Time PCR System (32 samples)
≤35 minutes
Singu20 Nucleic Acid Extractor AccuRa mini Real-Time PCR System (8-16 samples)
qPCR Detection Kits (PCR fluorescence method):
Respiratory Diseases: COVID-19, fluA, fluB, AdV, TB and multiplex of pre-surgical chemotherapy, indicating
test
Blood Diseases: HBV, HCV, HIV and multiplex test
Sexually Transmitted Diseases: HPV, CT, NG, UU and multiplex test
Viral Zoonotic Diseases: MPV
Vector-borne Diseases: PF, ZIKV
Genetic Diseases: MTHFR
Animal Diseases: Swine/Avian/Aquatic
Animal/Ruminant/Companion Animal Diseases
5-Part Hematology Analyzer Hematology + CRP +SAA Joint Analyzer (Auto Sampling)
others by activating its dye in the cancer's
acidic environment.
The MSOT device complements this
contrast agent by emitting infrared light
into the body, which activates the dye. This
interaction produces sound waves that the
MSOT device captures and translates into
a color-coded image. The resulting images
are so detailed that they can reveal cancer
cells usually undetectable by other means,
potentially revolutionizing pancreatic can-
cer surgery. This is particularly vital for
older patients, who are more commonly
affected by pancreatic cancer and face
higher risks from major operations, often
unable to undergo a second surgery. In
such cases, this new imaging technique
could significantly inform surgical planning.
For instance, if the MSOT detects cancer
invasion in critical blood vessels near the
pancreas, it would impact the surgical ap-
proach. It can also assess the effectiveness
whether cancer cells on blood vessels are
alive or if microscopic cancer remains.
Going forward, this innovative imaging
method holds the potential to become a
screening tool for those at heightened risk
of developing pancreatic cancer, such as
individuals with a family history or genetic
predisposition to the disease.
“This is a hybrid approach that accomplish-
es what a CT cannot,” said Lacey McNally,
Ph.D., professor of surgery at the OU College
of Medicine. “Pancreatic cancer often creates
tentacles that spread out beyond the primary
tumor. Currently, there is no way for the
surgeon to know where they are. But if the
surgery team can use this MSOT approach in
the operating room, it can tell them in real
time where the cancer has metastasized so
they can remove it.”

LINKXPRESS COM HMI-03-24 102

HospiMedica International
February-March/2024 2
HospiMedica
COVID-19 Update
International To view this issue in interactive digital magazine format visit www.HospiMedica.com
IVUS Improves Outcomes in
Cardiovascular Stenting Procedures
Cont’d from cover
ducing cardiovascular events. Despite this,
IVUS is utilized in only about 15-20% of PCI
cases in the United States, partly due to the
complexity of interpreting the images and
incomplete reimbursement for the proce-
dure. Optical coherence tomography (OCT),
another method that employs light rather
than sound to create images, delivers higher
resolution, more accurate, and detailed imag-
es than IVUS and is easier to interpret. How-
ever, OCT is only used in about 3% of PCI
cases, largely due to limited research data.
Individuals with coronary artery disease,
which involves plaque accumulation in
the arteries leading to symptoms like chest
pain, shortness of breath, and heart attacks,
often undergo percutaneous coronary inter-
vention (PCI). This non-surgical procedure,
conducted by interventional cardiologists,
involves using a catheter to place stents in
the obstructed coronary arteries to improve
blood flow. Typically, angiography guides
PCI, using a special dye and X-rays to visual-
ize blood flow and identify blockages in the
heart arteries. However, angiography has
its shortcomings, such as difficulty in accu-
rately assessing the true size of the artery,
the composition of the plaque, and issues
in confirming whether a stent is properly
expanded after PCI. It’s also less effective
in spotting other conditions impacting the
procedure’s early and late results.
Now, a new study by researchers at
Mount Sinai (New York City, NY, USA;
www.mountsinai.org) has found that using
intravascular imaging to guide stent place-
ment during PCI significantly enhances
patient survival and reduces adverse car-
diovascular events compared to relying on
angiography-guided PCI alone. The study,
published in The Lancet on February 21,
2024, is the largest and most compre-
hensive of its kind, comparing IVUS and
OCT against angiography-guided PCI. It
is the first study to demonstrate that these
I N T E R N A T I O N A L
www.hospimedica.com
A GLOBETECH PUBLICATION
Publishers of: HospiMedica International • LabMedica International
LabMedica en Español • HospiMedicaExpo.com • LabMedicaExpo.com
HospiMedica.com • HospiMedica.es • MedImaging.net
LabMedica.com • LabMedica.es
Marc Gueron Founder & Editorial Director
Dan Gueron Publisher
David Gueron Managing Editor
Sanjit Dutt News Editor
Carolyn Moody, RN Regional Director
Simone Ciolek Regional Director
Parker Xu Regional Director
Karina Tornatore Reader Service Manager
HOW TO CONTACT US
Subscriptions: www.LinkXpress.com
Send Press Releases to: HMNews@globetech.net
Advertising & Ad Material: ads@globetech.net
two high-resolution imaging techniques Other Contacts: info@globetech.net
can lower the rates of all-cause death, heart
attacks, stent thrombosis, and the necessity ADVERTISING SALES OFFICES
for revascularization.
In this study, the researchers evaluat- USA, UK Miami, FL 33280, USA
ed data from 15,964 patients undergoing Carolyn.Moody@globetech.net Tel: (1) 954-686-0838
PCI across 22 trials in various centers Joffre.Lores@globetech.net Tel: (1) 954-686-0838
from the United States, Europe, Asia, and
other regions between March 2010 and GERMANY, SWITZ., AUSTRIA Bad Neustadt, Germany
August 2023. Patients received either angi- Simone.Ciolek@globetech.net Tel: (49) 9771-1779-007
ography-guided PCI or intravascular imag-
BENELUX, FRANCE Hasselt, Belgium
ing-guided PCI using IVUS or OCT. During
a follow-up period ranging from 6 to 60 Nadia.Liefsoens@globetech.net Tel: (32) 11-22-4397
months, averaging two years, those who JAPAN Tokyo, Japan
received guidance via intravascular imaging
Katsuhiro.Ishii@globetech.net Tel: (81) 3-5691-3335
saw a 25% reduction in all-cause death,
45% reduction in cardiac death, 17% reduc- CHINA Shenzhen, Guangdong, China
tion in all myocardial infarctions, and 48% Parker.Xu@globetech.net Tel: (86) 755-8375-3877
reduction in stent thrombosis compared
ALL OTHER COUNTRIES Contact USA Office
to those who had angiography guidance.
The study also indicated that intravascular ads@globetech.net Tel: (1) 954-686-0838
imaging reduced target vessel myocardial
infarction by 18% and target lesion revas- SUBSCRIPTION INFORMATION
cularization by 28%, with similar outcomes
for both OCT-guided and IVUS-guided PCI. HospiMedica is published 4 times a year and is circuIat-
ed worldwide (outside the USA and Canada), without
“With these results, we now need to charge and by written request, to medical department
shift from performing more studies to de- chiefs and senior medical specialists related to critical
termine whether intravascular imaging is care, surgical techniques and other hospital-based
beneficial, to increasing efforts to over- specialties; hospital directors/administrators; and major
distributors/dealers or others allied to the field.
come the remaining impediments to the
To all others: Paid Subscription is available for a two-
routine use of OCT and IVUS, including year subscription charge of US$ 100. Single copy price
better training of physicians and staff and is US$ 20. Mail your paid subscription order accompa-
increasing reimbursement,” said Gregg W. nied with payment to Globetech Media, LLC, P.O.B.
Stone, MD, Director of Academic Affairs 800222, Miami, FL 33280-0222, USA.
for the Mount Sinai Health System. “In For change of address or questions on your subscription,
write to: HospiMedica lnternational, Circulation Services
this regard, we now have better ‘hard evi- at above address or visit: www.LinkXpress.com
dence’ that intravascular imaging guidance
of PCI procedures makes a greater impact
ISSN 0898-7270
to improving our patients’ lives than other
Vol.42 No.1 • Published, under license, by Globetech Media
routine therapies which are more widely LLC Copyright © 2024. All rights reserved. Rep­ro­duction in
used and reimbursed.” any form is forbidden without express permission.
Teknopress Yayıncılık ve Ticaret Ltd. Şti. adına
İmtiyaz Sahibi: M. Geren • Yazı işleri Müdürü: Ersin Köklü
Image: Intravascular ultrasound provides a Müşir Derviş İbrahim Sok. 5/4, Esentepe, 34394 Şişli, İstanbul
more accurate and specific picture of the P. K. 1, AVPIM, 34001 İstanbul • E-mail: Teknopress@yahoo.com
Baskı: Postkom A.Ş. • İpkas Sanayi Sitesi
coronary arteries (Photo courtesy of Adobe 3. Etap C Blok • 34490 Başakşehir • İstanbul
Yerel süreli yayındır. Yılda dört kere yayınlanır, ücretsiz dağıtılır.
Stock)
HospiMedica International
February-March/2024 4
 Susceptibility Tensor Imaging (STI)
Creates “Super-Scans” of the Brain

S
usceptibility Tensor Imaging (STI) is a specialized MRI tech- the most plausible solution for
nique that can measure the magnetic susceptibility of various each new scan set. This ma-
brain tissues. This process involves quantifying how these chine learning-enhanced algo-
tissues become magnetized in an MRI scanner's magnetic field. Such rithm is poised to make STI a
detailed information is crucial in enhancing understanding, diagnosis, more practical imaging choice
and monitoring of neurological diseases like multiple sclerosis (MS) for clinicians and radiologists
and Alzheimer's disease. Researchers have now made a significant ad- by reducing scan duration and
vancement by developing DeepSTI, a new algorithm that gathers data enhancing image quality.
from multiple scans to produce a comprehensive "super-scan" of the "Usually, STI imaging re-
brain. This scan offers precise information about brain tissue suscepti- quires at least six different
bility. Remarkably, DeepSTI requires fewer images and head positions scans at different head orienta-
than conventional STI, thus streamlining the process for patients. tions to achieve a good recon-
Developed by researchers at Johns Hopkins University (Baltimore, struction, and that's mainly
MD, USA; www.jhu.edu), this algorithm creates a detailed 3D map why it's not currently broadly
of the brain's magnetic susceptibility. Its primary breakthrough lies in used despite its potential to
its capacity to measure critical brain tissue components, such as my- understand the human brain,"
elin and iron, with fewer scans. Monitoring changes in these tissues said senior author Jeremias Su-
is essential for characterizing the type, stage, or progression of neuro- lam, an assistant professor of biomedical engineering. "Our AI-assist-
logical diseases. For instance, DeepSTI can visualize myelin changes ed reconstructions greatly expand the amount of useful information
in MS patients using data from a single head orientation scan. that can be gleaned while requiring much less data, and we hope that
DeepSTI leverages machine learning, particularly an approach will help move this imaging technique from lab to clinic."
known as regularization, which narrows the range of possible solu-
tions to the most accurate ones. The model uses special regularizers, Image: A new algorithm called DeepSTI takes data from multiple indi-
informed by previous scan data, to guide it towards optimal brain vidual scans and provides a `super-scan` of the brain (Photo courtesy
reconstructions. These data-driven regularizers lead the model to of Johns Hopkins University)

Pioneering Full-Body MRI Device Tracks

Moving Tumors in Real-Time During Proton Therapy

F
or the first time globally, scientists have combined a full-body duce high-contrast images of tumors, enabling more accurate differentia-
MRI device for real-time imaging with a proton therapy system tion of the tumor from adjacent healthy tissues. This precision allows for
in the form of a prototype. With this, experts from the fields of a more precise definition of the radiation target area. Moreover, MRI can
medicine, medical physics, biology, and engineering will now conduct track changes in the tumor’s size and shape across treatment sessions,
scientific testing of a new form of radiotherapy for treating cancer. facilitating the tailoring of the radiation beam to each patient’s unique
Scientists at Helmholtz-Zentrum Dresden-Rossendorf (HZDR, Dres- needs. Significantly, this technology also enables the visualization of
den, Germany; www.hzdr.de) and the Dresden University Medical Cen- tumor movement during radiation sessions, allowing for synchronization
ter (Dresden, Germany; www.tu-dresden.de) have ingeniously combined between the tumor’s movement and the application of radiation.
the capabilities of a full-body MRI machine, designed to rotate around the Creating this novel system presented substantial technological chal-
patient, with a proton therapy system. This combination aims to enhance lenges, particularly due to the interaction between the magnetic fields
the precision of proton therapy for cancer patients by utilizing
vc HospiMedica_clr_3.75x7.5_Eng24Feb08_12868.pdf 1 real-time
2/5/24 1:10used
PM in both the MRI device and the proton radiation system. These
MRI imaging during treatment.
vc HospiMedica_clr_Eng MRI’s
7.625 x 3.5 due superiority lies in its ability to pro-
2/8/2024 Cont’d on page 6

New X-ray QA SOFTWARE

Accu-Gold 3
• Optimize Work Time
– Machine Specific Profiles
– Favorites Folder
– Advanced Mammography:
Single Exposure Combo-mode
– Advanced CBCT Dental:
Simultaneous DAP, kV and Dose
• More Values Displayed
For further details: Visit us at MD Expo #3312, 4/7-4/9
Contact us at +1 (626) 357-7921 • sales@radcal.com or www.radcal.com

5 HospiMedica International
February-March/2024
LINKXPRESS COM HMI-03-24 105
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

SOLID STATE KV/DOSE MULTI-SENSOR PACS WORKSTATION CT BRAIN IMAGING SOFTWARE

RADCAL PAXERAMED SHINA SYSTEMS

The AGMS-DM+ is a solid-state kV/dose multi-sensor
for diagnostic and mammographic range measure-
ments. It measures dose, dose rate,
time, kVp w/ FFT analysis, HVL,
beam filtration, and features correc-
tion of dose for beam quality.
PaxeraView PRO is a powerful, stand-alone PACS
workstation allowing users to securely archive and
easily access patient images. Ideal
for small facilities, it incorporates
a complete diagnostic viewer and
universal web-viewers.
3Di Brain Perfusion is a powerful application for the
evaluation of brain perfusion. It calculates and dis-
plays optimized color result maps for
CBV, CBF, MTT, and TTP, mirroring
ROIs about the midline of the brain.

LINKXPRESS COM HMI-03-24 201 LINKXPRESS COM HMI-03-24 202 LINKXPRESS COM HMI-03-24 203

New PET Tracer Detects

Inflammatory Arthritis Before
Symptoms Appear

R
heumatoid arthritis, the most common form of inflammatory
arthritis, affects 18 million people globally. It is a complex
autoimmune disease marked by chronic inflammation, lead-
ing to cartilage and bone destruction, functional limitations, disability,
decreased quality of life, and potentially reduced life expectancy. A
significant focus in rheumatology is the use of precision diagnostics to
predict the onset of rheumatoid arthritis in individuals with risk factors.
The goal is to identify such individuals before they exhibit symptoms,
enabling early treatment to prevent the disease's development. Now, a
novel PET imaging technique can noninvasively detect active inflamma-
tion in the body, even before clinical symptoms emerge.
CD69, an early marker of cell inflammation, is found in the tissue
68
of patients with active rheumatoid arthritis. Using Ga-DOTA-ZCAM241, a
CD69-targeting PET agent that binds to proteins present in activated im-
mune cells, researchers at the Karolinska Institutet (Solna, Sweden; www.
ki.se) showed that the technique produces images of ongoing inflamma- Image: The PET imaging technique can noninvasively detect active
tion throughout the body, such as rheumatoid arthritis. This makes it easi- inflammation before clinical symptoms arise (Photo courtesy of
er for physicians to correctly diagnose and treat patients. In their study, the 123RF)
68
researchers evaluated the performance of the Ga-DOTA-ZCAM241 for early
disease detection in a mouse model of inflammatory arthritis.
In the study, which was published in the February issue of The Pioneering Full-Body MRI Device
Tracks Moving Tumors in Real-Time
68
Journal of Nuclear Medicine, mice underwent Ga-DOTA-ZCAM241 PET
imaging before and at various intervals after arthritis induction. Dis-
ease progression was monitored through clinical parameters like body
During Proton Therapy
Cont’d from page 5
68
weight and paw swelling. Analysis of Ga-DOTA-ZCAM241 uptake in the
paws was conducted, and CD69 expression was examined in tissue interactions can potentially affect both the quality of the imaging and
biopsies post the final PET scan. A control group of mice was scanned the accuracy of the proton beam application. Building on the success
using a nonspecific control peptide. The results showed increased up- of a previous prototype that demonstrated the technical feasibility of
68
take of the CD69-specific tracer Ga-DOTA-ZCAM241 in the paws of mice simultaneous radiation and imaging, this latest development marks the
with induced inflammatory arthritis as early as three days post-induc- first-ever use of real-time MRI imaging in this context. The research
tion, preceding clinical symptom manifestation by five to seven days. team plans to use this prototype in future studies to assess its potential
The tracer uptake also corresponded with clinical scores and disease se- benefits, particularly for mobile tumors located in areas like the chest,
verity, while the nonspecific control peptide showed minimal binding. abdomen, and pelvis.
68
“ Ga-DOTA-ZCAM241 is a potential candidate for PET imaging of “This new prototype with integrated full-body MRI makes it possible
activated immune cells during rheumatoid arthritis onset,” said Olof to visualize moving tumors using high-contrast real-time imaging. Our
Eriksson, PhD, associate professor at Uppsala University. “We know work aims to develop a technique to irradiate tumors only when they
that physicians are asking for better methods to image inflammation, are hit reliably by the proton beam,” said Prof. Aswin Hoffman who
for example in rheumatoid arthritis, and we hope this technology will developed the new system. “The MRI device, which can rotate around
be broadly used in many diseases that involve activated immune cells the patient, enables us to use innovative types of patient positioning for
and inflammation.” proton therapy in both lying or in upright positions.”

HospiMedica International
February-March/2024 6
 Medical
To view this issue in interactive digital magazine format visit www.HospiMedica.com
Imaging

Ultrafast Ultrasound Imaging

Technique Captures 1000 Images
per Second

T
he kidney’s critical role in filtering waste and excess substances
from the bloodstream can be severely impacted by conditions
like hypertension and diabetes, potentially leading to kidney
failure. This irreversible condition requires lifelong management through
artificial hemodialysis or kidney transplantation. The direct connection
between blood perfusion in the kidneys and their filtration function
makes microvascular imaging a crucial tool for both the prevention and
treatment of kidney failure.
Image: Vascular changes in acute and diabetic renal failure
Contemporary imaging techniques such as computed tomography
(Photo courtesy of POSTECH)
(CT) and magnetic resonance imaging (MRI) face challenges in accu-
rately capturing fine vascular structures. This is due to their inherent and after kidney transplantation,” said Professor Chulhong Kim. “It has
limitations in resolution and sensitivity. Additionally, in patients with significant potential to be used to study blood circulation and functional
kidney disease, the use of contrast agents in these methods is limited due impairment across various organs including the digestive system, circu-
to the risk of potentially fatal side effects. On the other hand, ultrasound latory system, and cerebral nervous system.”
imaging, known for its safety even in
fetal monitoring, uses the Doppler ef-
fect to measure blood flow velocity and
direction in real time without requiring
contrast agents. However, traditional
ultrasound imaging speeds are not suf-
ficient to capture the fine blood vessels
with the necessary sensitivity.
A research team at Pohang Univer-
sity of Science and Technology (POS-
TECH, Pohang, South Korea; www.
postech.ac.kr) has realized significant
advancements in microvascular sensi-
tivity. They have achieved this by em-
ploying ultrafast ultrasound acquisition
techniques that capture images at 1,000
frames per second, over 100 times fast-
er than conventional ultrasound meth-
ods. This breakthrough allowed them
to image the three-dimensional micro-
vasculature of the kidneys without the
need for any contrast agents. In a
pioneering feat, they achieved imaging
of the entire three-dimensional vascular
network of the renal artery, vein, and
the minute 167μm (micrometer) thick
interlobular arteries and veins in the AWA K E N I N G
renal cortex.
Additionally, the team conducted a
continuous observation of renal vascu-
lar changes in an animal model with
induced renal failure. Through this, they
performed a multivariate analysis us-
ing various hemodynamic and vascular
morphological indicators. Their findings
revealed a significant decrease in renal
blood flow during acute renal failure.
In cases of diabetic nephropathy, they
observed chronic vascular degeneration
in the kidneys, characterized by vascu-
lar distortion. This innovative imaging
technique holds promise in revolution-
izing the monitoring and treatment of
kidney diseases. VIENNA / F E B R UA RY 2 8 – M A RC H 0 3
“The system allows us to under-
M Y E S R . O RG
stand the pathophysiology of diseases
leading to kidney failure, enabling the THE ANNUAL MEE TING OF

observation of vascular changes before

7 HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

RADIATION THERAPY QA MANAGEMENT UHF MRI SYSTEM MAMMOGRAPHY SYSTEM

PLATFORM SUN NUCLEAR UNITED IMAGING HEALTHCARE SIEMENS HEALTHINEERS

SunCHECK Patient is a quality management platform
for radiation therapy that streamlines data transfer
and time-consuming tasks. In sup-
port of standardization, SunCHECK
Patient offers common analyses
across each Patient QA phase.
The uMR Jupiter 5T is the world’s first whole-body ul-
tra-high field (UHF) MRI, representing a breakthrough
in the evolution of MRI. The new
5.0T superconducting magnet and
RF system are designed using state-
of-the-art technology.
The MAMMOMAT B.brilliant brings the next genera-
tion of 3D mammography, featuring PlatinumTomo, a
completely new tomosynthesis im-
age acquisition technology. It offers
a 50° wide-angle tomosynthesis
scan time of just five seconds.

LINKXPRESS COM HMI-03-24 204 LINKXPRESS COM HMI-03-24 205 LINKXPRESS COM HMI-03-24 206

New Helmet with Tiny Sensors Could

Conduct Brain Scans of People in Motion

R
esearchers have created a pioneering helmet equipped
with miniature LEGO-sized sensors capable of scanning
the brain while a person is in motion. This groundbreaking
development, led by the University of Nottingham (Nottingham, UK;
www.nottingham.ac.uk), marks a significant leap in brain scanning
technology. Previously, capturing accurate magnetic fields gener-
ated by brain activity was only possible when a person remained
stationary. This new lightweight helmet paves the way for easier
brain scans in young children and those with neurological disorders
who may find it challenging to stay still in traditional scanners. It's
adaptable to various head sizes and shapes, opening new avenues
for understanding brain development and the changes occurring in
neurological conditions such as autism, epilepsy, stroke, concussion,
and Parkinson's disease.
When neurons in the brain interact, they produce a tiny electric
current that generates a magnetic field. This field is detectable and re-
cordable through a process known as magnetoencephalography (MEG).
MEG technology is capable of capturing both normal and abnormal
brain signals with millisecond precision, and its results can be superim-
posed on an anatomical brain image to pinpoint the origins of specific
brain activities. Traditional MEG systems, resembling old-fashioned
hair dryers, require the subject's head to remain still and have sensors
that need to be cooled to freezing temperatures or below, preventing
direct contact with the scalp.
The research team at Nottingham used advanced optically
pumped magnetometers (OPMs) for their helmet, which function at
room temperature and can be placed close to the head, significantly
enhancing data quality. The flexible design of the sensors allows
for movement during scanning, addressing a major limitation of
conventional MEG systems. However, OPMs require an environ-
ment free from background magnetic “noise” to ensure high-quality
recordings. To tackle this, the team devised a magnetic shielding
system capable of negating or compensating for these interfering
magnetic fields.
They built a system with electromagnetic coils, arranged on two
panels around the participant, to shield against background noise.
Previous research utilized eight large coils that limited head move-
ment due to their fixed position. The Nottingham team innovated
a matrix coil system with 48 smaller coils on two panels, allowing
individual control and continuous recalibration to counteract mag-
netic field fluctuations caused by sensor movement. This setup
guarantees high-quality MEG data recording in any position, making
Image: The brain scanning helmet with sensors records brain function
(Photo courtesy of Virginia Tech)
OPM-MEG scans more comfortable and accommodating for individ-
uals to move around.
The efficacy of this new matrix coil system was validated through
four experiments. Initially, they confirmed that the helmet, when
stationary and placed within the coil panels, effectively reduced
background magnetic fields. A subsequent test with a healthy partic-
ipant wearing the helmet demonstrated successful recording of brain
function during head movement, with the coils effectively canceling
out magnetic fields. Another experiment involved a wire coil attached
to the helmet, which mimicked brain cell activity and confirmed the
system's ability to compensate for motion-related changes. Finally, a
second participant wearing the helmet illustrated the system's capa-
bility to produce high-quality brain activity recordings while walking
around.
“Unconstrained movement during a scan opens a wealth of possi-
bilities for clinical investigation and allows a fundamentally new range
of neuroscientific experiments,” said Niall Holmes, Ph.D., a Mansfield
Research Fellow in the School of Physics and Astronomy at the Univer-
sity of Nottingham, who led the research.
“By taking advantage of recent OPM-MEG technology and designing
a new magnetic shielding system, this helmet represents a novel mag-
netoencephalography approach that could help reveal more about how
the brain works,” said Shumin Wang, Ph.D., a program director in the
NIBIB Division of Applied Science & Technology (Bioimaging).

HospiMedica International
February-March/2024 8
 Medical
To view this issue in interactive digital magazine format visit www.HospiMedica.com
Imaging

Identifying Higher Risk of TB Infection

Cont’d from cover itive baseline Actiphage test and subsequent
release assay (IGRA), can detect an immune treatment for high-risk TB infection features.
response to TB but fail to differentiate between Actiphage results were positive in 12 (60%) par-
those at high or low risk of disease progres- ticipants at baseline and in all six of the treated
sion. This limitation underscores the need for PET-CT-positive participants. The study’s find-
improved testing methods to identify individ- ings led the researchers to propose that blood
uals at higher risk of developing TB, allowing biomarkers aimed at detecting bacterial pres-
for more focused preventative treatment. Re- ence could complement existing biomarkers of
searchers have now introduced an innovative the host immune response, thus improving the
approach to studying the progression of TB stratification of TB risk in individuals with TB Image: Novel approach identifies people at risk
from infection to disease, identifying and treat- infection. of developing TB (Photo courtesy of 123RF)
ing individuals at increased risk who might be “Our results are exciting for two reasons.
missed by existing testing methods. Firstly, they show that PET-CT could be in Respiratory Medicine at the University of
Researchers at the University of Leices- an effective tool for identifying people with Leicester. “Secondly, our findings suggest
ter (Leicester, UK; hwww.le.ac.uk) employed higher risk TB infection. This can help us that TB bacteria are found in blood more
PET-CT, an advanced imaging technique, to to perform studies to develop new tests and often than has previously been thought and
study how TB infection progresses and to evaluate new treatments, including vaccines importantly, the presence of the bacteria in
identify individuals at higher risk of developing more efficiently and at lower cost,” said Dr. blood may be an indicator of uncontrolled or
the disease. This method enabled the team to Pranabashis Haldar, Clinical Senior Lecturer progressive TB infection.”
evaluate a potential new blood test to
identify those at higher risk without
the need to recruit a large and costly
cohort. The study involved 20 adults
Digital Microscopy and AI
linked to households of individuals
Clinical and Research Applications
being treated for TB. These participants
underwent chest radiography and IG-
RA screening for TB infection. The
research team then utilized two novel
methods to monitor disease progres-
sion over the next year: PET-CT imag-
ing and a unique bacteriophage-based
assay called Actiphage, developed by
PBD Biotech (Saskatoon, Canada;
www.pbdbio.com). Actiphage utilizes
bacteriophages, viruses that specifically
infect bacterial cells, to target TB bac-
teria. When the bacteriophage infects
TB bacteria, it releases bacterial DNA,
which can then be detected, even at
very low levels that other clinical tools
cannot identify.
All participants in the study were as-
ymptomatic with normal chest X-rays.
They first underwent a baseline PET-
CT scan. If the scan showed metabolic
activity indicative of TB that could be
sampled, they underwent bronchosco-
py and sampling. Participants without
sampleable findings on the initial PET-
CT, or with negative sampling results,
received a follow-up PET-CT scan after
three to four months. Through PET-CT,
the researchers identified four indi-
viduals from whom TB bacteria were
isolated either from the lung airway or
from PET-positive lymph nodes. Addi-
tionally, two more participants showed
progressive changes on the second PET-
CT scan. All six individuals received TB
treatment, and follow-up PET-CT scans
three months post-treatment showed
resolving or completely resolved chang-
es, suggesting the PET-CT changes
were due to active TB infection.
The Actiphage test results were also
promising. The researchers observed a
significant correlation between a pos-

9
LINKXPRESS COM HMI-03-24 109
HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE
MOBILE X-RAY BARRIER
CLEAR IMAGE DEVICES
The Lead Acrylic Mobile X-Ray Barriers are designed
to provide full-body shielding and feature a durable,
shatter-resistant construction. They
feature an optically clear lead-acryl-
ic viewing panel offering superior
visibility.
LINKXPRESS COM HMI-03-24 207
Wearable Ultrasound Predicts Liver Failure
Cont’d from cover
nique, akin to ultrasound imaging, involves
a technician using a handheld probe over the
skin to send sound waves into the body. These
waves cause slight vibrations in internal organs,
generating returning waves. The probe detects
these vibrations, and their pattern is trans-
lated into a measure of the organ’s stiffness.
Ultrasound elastography is mainly utilized in
intensive care units to monitor post-transplant
patients, allowing technicians to check the
new organ for signs of stiffening, acute failure,
or rejection. However, continuous long-term
monitoring isn’t feasible with this method,
creating a risk of missing critical changes. Now,
an ultrasound sticker previously developed to
image deep tissues and organs could offer a
more continuous, wearable alternative.
Engineers at MIT (Cambridge, MA, USA;
www.web.mit.edu) have developed a small
ultrasound sticker, roughly the size of a post-
age stamp, capable of monitoring deep internal
organ stiffness. When worn on the skin, this
sticker can detect signs of diseases like liver
and kidney failure or the progression of solid
Wearable Ultrasound Non-Invasively Treats Chronic Limb-Threatening Ischemia
P
eripheral arterial disease (PAD) is a
condition affecting millions globally,
where peripheral arteries become
narrowed, restricting blood flow from the
heart to other body parts. PAD patients with
extreme blockages can progress to Chron-
ic Limb-Threatening Ischemia (CLTI), expe-
riencing severe pain, non-healing sores, and
wounds, often leading to limb amputation.
Now, a novel, non-invasive, wearable ther-
apeutic ultrasound device designed to treat
CLTI and PAD can improve tissue perfusion,
reduce symptoms, and save limbs.
Vibrato Medical (Newport Beach, CA, USA;
www.vibratomedical.com) is developing the
first wearable therapeutic ultrasound device
designed to promote vasodilation and vessel
To receive prompt and free information on products, log on to
www.linkXpress.com or scan the QR code on your mobile device
MAMMOGRAPHY FLAT PANEL DETECTOR
CARERAY DIGITAL MEDICAL SYSTEM
The 750M Flat Panel Detector (FPD) is designed for
low-dose breast screening and tomosynthesis, offer-
ing a 10″ x 12″ imaging area, and
utilizing a perfect balance of HDR
pixel design and direct-deposit CsI
technology.
LINKXPRESS COM HMI-03-24 208
tumors. The sticker emits sound waves that
penetrate the skin and reflect off internal
organs, with the returning wave patterns indi-
cating organ rigidity. The team has successfully
demonstrated that the sticker can continuous-
ly monitor organ stiffness for up to 48 hours,
detecting subtle changes indicative of disease
progression. In early experiments, the sensor
identified signs of acute liver failure in rats.
Currently, the engineers are modifying the
sticker’s design for human application. They are
collaborating with clinicians to adapt the sticker
for use in ICU patients recovering from organ
transplants. The design is expected to remain
largely unchanged for this application, with
the sticker attaching to a patient’s skin. Sound
waves sent and received by the sticker can be
processed by connected electronics, similar to
EKG machines. The team also aims to develop
a more portable, self-contained version of the
sticker, incorporating all necessary electronics
and processing into a larger patch. This advance-
ment could enable patients to wear the sticker at
home for extended periods, continuously mon-
itoring conditions like the progression of solid
growth. Based on decades of therapeutic ul-
trasound research and the latest technologi-
cal advancements, Vibrato’s technology is the
first wearable therapeutic ultrasound device
designed to promote vasodilation and vessel
growth. Unlike endovascular and surgical revas-
cularization, Vibrato’s technology can be applied
without a single skin incision. Therapeutic ultra-
sound, the scientific basis of Vibrato’s approach,
has been validated through animal and clinical
studies that found it demonstrated vasodilation,
collateral vessel growth, and angiogenesis.
Vibrato has now announced that data from
an early feasibility study of non-invasive thera-
peutic ultrasound (TUS) to treat CLTI has suc-
cessfully met its endpoint. The study evaluated
patients with infrapopliteal PAD and measured
COMPUTED TOMOGRAPHY (CT) SCANNER
CANON
The Aquilion Serve SP computed tomography (CT)
scanner offers high-quality, low-dose imaging while
increasing efficiency, consistency,
and throughput. It combines the
power of AI-enabled technologies
with a redesigned workflow.
LINKXPRESS COM HMI-03-24 209
Image: The sticky, wearable sensor senses
changing stiffness of deep internal organs
(Photo courtesy of MIT)
tumors, which tend to harden as they worsen.
“When some organs undergo disease, they
can stiffen over time,” said Xuanhe Zhao,
professor of mechanical engineering at MIT.
“With this wearable sticker, we can contin-
uously monitor changes in rigidity over long
periods of time, which is crucially important
for early diagnosis of internal organ failure.”
“We believe this is a life-saving technology
platform,” Zhao added. “In the future, we think
that people can adhere a few stickers to their
body to measure many vital signals, and image
and track the health of major organs in the body.”
changes in foot perfusion and oxygenation as
well as therapy tolerance, compliance, and
perception. Participants, categorized as having
Rutherford class 3, 4, or 5 PAD, underwent 30-
40 TUS treatment sessions over two months.
Remarkably, each participant exhibited statis-
tically significant improvements in perfusion
post-treatment, demonstrating the potential of
this device to revolutionize treatment for indi-
viduals suffering from severe PAD and CLTI.
“These early findings are promising for the
future of non-invasive therapeutic options to
treat chronic limb-threatening ischemia,” said
Juliana Elstad, CEO at Vibrato. “We’re looking
forward to building on these findings as we
begin our next prospective multi-center ran-
domized clinical trial.”
HospiMedica International
February-March/2024 10
 Tiny Ear Canal Device
Monitors Heart Health

W
earables such as smartwatches that are capable of monitoring
functions can provide details of an individual’s heartbeat but
cannot accurately and unobtrusively measure the electrical
current of the heart, which can help diagnose an irregular heartbeat.
Now, a study has shown for the first time that tiny devices, situated
in a single ear, can effectively capture electrocardiogram (ECG) data
in real time. This innovation marks a significant advancement toward
monitoring heart health more precisely.
The research, conducted by a team at Imperial College London
(London, UK; www.imperial.ac.uk), builds on their previous work
where they identified the ear as a viable location for monitoring brain
functions and vital signs through “hearable devices” – wearables that
fit comfortably within the ear canal. The team also pioneered an ear-
ECG technology, where electrodes placed in both ears can generate
valid electrocardiograms. This new study, however, explored the
potential of using hearables for cardiac health monitoring from just
one ear, a concept not yet thoroughly established. To validate their
approach, the Imperial College team examined ECG signals and
mapped the chest-ECG potential across the ear, neck, and scalp areas.
They then tested the feasibility of single ear-ECG measurements under
real-world recording conditions.
The study successfully measured cardiac cycles using electrodes
placed around the ear region, confirming the accuracy of ECG signals
obtained from a single ear-ECG in terms of their shape and timing. The
researchers envision that this technology could eventually be used for
continuous 24/7 monitoring of various groups such as patients and Human - Veterinary - Bio-Threat
athletes. It could also be employed to assess the impact of physical
strain and stress in different workplace environments, offering a more Diagnostics/ Research/ Forensic
non-invasive and continuous method of monitoring heart health.
“The significance of our findings lies in the high practicality and
usability of the single ear-ECG,” said Metin Yarici, lead author of the
QuickProfile TM QuickStatus®
study published in the Royal Society Journal of Open Science in Janu- Quicknostics® EnviroSafe TM
ary 2024. “We believe that this method holds great promise in bringing
continuous cardiac motoring out of a clinical setting and into society, SAFE TM
and with it, new insights into heart functioning for healthy and patient
populations alike. An important next step in this research is to test the
feasibility of detecting specific abnormalities in heart function, such
as atrial fibrillation or myocardial infarction, via the single ear-ECG.”
Image: Research shows how a tiny device in the ear canal can monitor
heart health (Photo courtesy of Danilo Mandic)

Self-Propelling Nanorobots
Reduce Bladder Tumors by 90%

B
ladder cancer is one of the most common cancers worldwide, Infectious Diseases Drugs of Abuse Cancer Markers
especially among men where it ranks fourth. It has a high re-
currence rate, with about half of the cases recurring within five Cardiac Markers Hormones Veterinary Tests
years, creating the need for continuous monitoring. This constant need Oxidative Stress Bio-Threat Agents
for follow-up and repeated treatments makes bladder cancer treatment
one of the costliest. While current treatments, which involve adminis-
tering drugs directly into the bladder, offer favorable survival rates, their Visit us at the
therapeutic effectiveness is still limited. An emerging and promising ADLM 2024
approach is the use of nanoparticles, particularly nanorobots, that can Clinical Lab Expo
self-propel and deliver therapeutic agents directly to cancer cells. BOLD MOVE.
A recent breakthrough by scientists at IRB Barcelona (Barcelo-
JULY 28-AUGUST 1 • CHICAGO, IL Booth 2160
na, Spain; www.irbbarcelona.org) has demonstrated the potential of
urea-powered nanorobots in bladder cancer treatment. In their study, the
team achieved a significant 90% reduction in bladder tumor size in mice www.LumiQuick.com
using a single dose administered by these nanorobots. The nanorobots
are essentially tiny machines, composed of porous silica spheres. Their www.QuickProfileDOA.com
surfaces are equipped with various components, each serving a specific sales@LumiQuick.com
purpose. One key component is the enzyme urease, which reacts with
urea in urine, propelling the nanorobot forward. Another crucial element +1(408)855-0061
Cont’d on page 12

11
LINKXPRESS COM HMI-03-24 111
HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

NSPIRO SPIROMETER SYSTEM INFANT INCUBATOR TROLLEY LUNG VENTILATOR

NORAV MEDICAL OKUMAN MEDIKAL SIARE

NSpiro Spirometer System provides fast and accurate
pulmonary analysis and reliable Spirometry mea-
surements. It is optimal for asthma
management, early detection of
respiratory disorders, and pharma-
ceutical trials.
The OKM 801 infant incubator monitors skin tem-
peratures and ambient temperatures, and provides
access to the baby from four sides
of the canopy. It features an 8″ LCD
color screen and allows an optional
external control screen.
ARIA 150 is the latest generation lung ventilator on a
trolley with a turbine flow generator making it autono-
mous from compressed air. It offers
a wide range of operating modes
suitable for invasive and non-inva-
sive ventilation.

LINKXPRESS COM HMI-03-24 210 LINKXPRESS COM HMI-03-24 211 LINKXPRESS COM HMI-03-24 212

Catheter Prevents Bacterial Infections

Cont’d from cover
searchers have developed a novel catheter tube that significantly ham-
pers the ability of bacteria to move upstream, effectively reducing the
potential for infections without relying on antibiotics or other chemical
treatments. This new design, optimized through advanced artificial
intelligence (AI), has shown a remarkable 100-fold reduction in the
number of bacteria swimming upstream in laboratory experiments.
Fluid inside catheter tubes exhibits what’s known as Poiseuille flow,
where the fluid moves faster in the center and slows near the walls.
Bacteria exploit this by using a unique motion, moving forward along
the walls and then back in the middle, to progress through the tube.
Researchers at California Institute of Technology (Caltech, Pasadena,
CA, USA; www.caltech.edu) decided to tackle this problem with sim-
ple geometries by designing tubes with triangular protrusions, similar
to shark fins, lining the tube’s walls. Simulated models demonstrated
that these structures effectively redirect bacteria towards the center of
the tube where the faster flow sweeps them back downstream. Addi-
tionally, the triangles’ fin-like curvature creates vortices that disrupt the
bacteria’s progress. The researchers then set out to verify the design
experimentally with the help of additional biology expertise. The team
was supported by their previous research into the navigation mecha-
nisms of the nematode Caenorhabditis elegans, a rice grain–sized soil
organism commonly studied in research labs, providing them with the
tools needed to observe and analyze the movements of microscopic
organisms. They utilized 3D printing to create these specially designed
catheter tubes and employed high-speed cameras to track bacterial
movements. The results were significant, showing a two-order magni-
tude decrease in the ability of bacteria to swim upstream.
Image: Diagram of new catheter design (Photo courtesy of Caltech)
Further simulations were conducted to identify the most effective
shape for the triangular obstacles. The team created microfluidic
channels, mimicking common catheter tubes, with these optimized
triangular designs. Observations of E. coli bacteria moving through
these channels closely matched their simulations. To enhance the
design further, the team employed advanced AI techniques known as
neural operators, drastically reducing the computation time from days
to minutes. This AI-optimized model suggested slight modifications
to the triangle shapes, boosting their efficacy by an additional 5% in
preventing bacteria from swimming upstream. This groundbreaking
design represents a significant stride in medical technology, offering
a safer and more efficient way to prevent catheter-associated urinary
tract infections without the need for antibiotics, marking a significant
advancement in patient care and infection control.
“Our journey from theory to simulation, experiment, and, finally,
to real-time monitoring within these microfluidic landscapes is a com-
pelling demonstration of how theoretical concepts can be brought to
life, offering tangible solutions to real-world challenges,” said Tingtao
Edmond Zhou, a co-first author of the study, which was published in
the journal Sciences Advances on January 3, 2024.

Self-Propelling Nanorobots Reduce Bladder Tumors by 90%

Cont’d from page 11
is radioactive iodine, widely used in localized tumor treatment.
Understanding how these nanorobots penetrate the tumor was
challenging, as they do not possess specific antibodies for tumor recog-
nition and because tumor tissue is generally stiffer than healthy tissue.
However, the team discovered that the nanorobots could break down
the tumor's extracellular matrix by locally increasing pH through their
self-propelling action. This action enhances their penetration into and
accumulation within the tumor. The researchers observed that while the
nanorobots collide with the urothelium, acting as if they hit a wall, they
effectively penetrate and accumulate inside the spongier tumor tissue.
The mobility of these nanobots significantly increases their chances
of reaching and impacting the tumor. Additionally, the localized delivery
of these nanorobots, carrying the radioisotope, reduces potential side
effects. The high accumulation of these nanorobots in tumor tissue also
intensifies the radiotherapeutic impact. This research offers promising
directions for bladder cancer treatment, potentially reducing hospital
stays, lowering costs, and improving patient comfort. The next re-
search phase is already in progress, focusing on whether tumors recur
post-treatment with these nanorobots.
"With a single dose, we observed a 90% decrease in tumor volume.
This is significantly more efficient given that patients with this type
of tumor typically have 6 to 14 hospital appointments with current
treatments," said Samuel Sánchez, ICREA research professor at IBEC
and leader of the study. “Such a treatment approach would enhance
efficiency, reducing the length of hospitalization and treatment costs.”
HospiMedica International
February-March/2024 12
 Critical
To view this issue in interactive digital magazine format visit www.HospiMedica.com
Care

World’s First Safe Electric

Drug Infusion Pump to Prevent
Medical Accidents

M
edical mishaps caused by the over-administration of pain relief
medication during or post-surgery can lead to fatalities, particularly in
surgery and cancer treatment scenarios. These incidents often arise
from issues with drug infusion pumps or errors in medical supplies. To prevent
such accidents, researchers have developed the world’s first drug infusion pump
with a safe medication administration detection technology.
A research team at the Korea Institute of Machinery and Materials
(KIMM, Daejeon, South Korea; www.kimm.re.kr) has successfully created
the technology for customized sensor modules. These modules are designed
to measure the very low flow rates typical of analgesic drug infusion pumps,
as well as to detect air bubbles within these pumps. To manage post-operative
pain, narcotic analgesics are usually administered at flow rates as low as 1
to 2 mL/h. The team developed a novel thermal micro-flow sensor, which
incorporates a micro-heater and multiple temperature sensors, to accurately
gauge these minimal flow rates. This was achieved by balancing the cooling Image: Integrated drug infusion pump with flow and bubble sen-
effect on the microheater due to heat loss and its heating effect on the fluid. sor modules (Photo courtesy of KIMM)
In line with updated FDA regula-
tions requiring bubble sensors in drug

ESC
infusion pumps, the new pumps are
equipped with temperature sensors at
both ends of the tube. These sensors

Congress
can detect bubbles by observing the
variation in heat diffusion between
air and liquid in the tube. Notably, by
attaching the sensor to the exterior

2024 London
of the drug injection tube, both the
flow rate and bubble presence can be
measured non-invasively. This design
also allows for sensor reuse, address-
ing the cost issues related to medical
disposables.
This technology ensures perfor-
mance on par with high-cost MEMS
sensors in terms of sensitivity, accu-
30 August –
racy, measurement range, and bub-
ble detection. The sensor has been
2 September
developed as a customized module to
replace the ultrasonic bubble sensor Onsite & Online
in existing drug infusion pumps. This
sensor module is currently being pre-
pared for large-scale production for use
in new drug infusion pumps. The in- Abstract submission: 12 December - 1 March
troduction of this technology is poised Clinical Case submission: 16 January - 8 March
to play a significant role in preventing
medical accidents caused by excessive Late-Breaking Science submission: 27 March - 6 June
analgesic administration post-surgery. Early registration deadline: 31 May
It is also expected to facilitate speedy
medical services by providing highly Late registration deadline: 31 July
accurate data on medication speed Last-minute registration until: 2 September
and dosage and to reduce the medi-
cal staff’s workload in drug injection
management.
“This is a technology for a sensor
capable of simultaneously measuring
extremely low flow rates and bubbles Your journey to the
without coming into contact with the
drug outside the tube and without having heart of cardiology
to apply the expensive MEMS sensor
technology, simply by attaching the drug
infusion tube to the sensor,” said senior
researcher Dong-kyu Lee of the KIMM. #ESCCongress
“It is a technology that is customized for
the injection of medications.”

13 HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

TOUCH SPIROMETER CRITICAL CARE TRANSFER TROLLEY BLADDER SCANNER

SIBEL GROUP PARAID MEDICAL SYSTEMS COMSSEN INDUSTRIAL CO.

The DATOSPIR touch spirometer features an au-
tomatic quality-control function with messages that
help the technician provide good
instructions to the patient to obtain
high-quality spirometry test results.
The Transporter Infinite Neo is a critical care transfer
trolley designed specifically for neonates that pro-
vides the clinical team with a safe
and secure method of transfer of
neonates and medical equipment by
ambulance.
The Z3 Bladder Scanner is a real-time ultrasound
bladder scanning device that accurately measures
bladder volume and PVR. Its great
portability, small size, and ultra light-
weight scanner console make it ide-
al for ‘use on the go’.

LINKXPRESS COM HMI-03-24 213 LINKXPRESS COM HMI-03-24 214 LINKXPRESS COM HMI-03-24 215

ECG Vest Allows For Non-Intrusive,

Non-Invasive Heart Monitoring

A
n arrhythmia, an irregular heartbeat, can lead to serious
health issues like blood clots, stroke, and heart failure. Tra-
ditional methods for monitoring such arrhythmia, like the
Holter monitor, have limitations in terms of wearability and duration,
typically offering only a 24- or 48-hour observation window. More long-
term solutions tend to be invasive, requiring anesthesia for insertion.
Now, an ECG monitoring system integrated into a T-shirt can accurately
and non-invasively monitor the patient’s heart for weeks or months.
PA Consulting (London, UK; www.texasheart.org) has developed Vis-
cero, a revolutionary approach to ECG monitoring that integrates sensory
technology seamlessly into a vest, allowing for effortless capture and trans-
mission of diagnostic-quality data. The system positions dry electrodes in
peripheral locations away from the chest, ensuring constant compression
points for accurate readings. The brain behind Viscero, similar in size to
a matchbox, conveniently fits into a pocket on the T-shirt. This allows for
easy removal for recharging purposes or when the T-shirt needs washing.
Additionally, Viscero is equipped with an onboard accelerometer and gyro-
scope, enriching the heart signal data with contextual information about
the wearer’s physical activities preceding an arrhythmic event.
This comprehensive data is accessible through an AI-enhanced dash-
board that categorizes recordings into potential arrhythmic episodes, facil-
itating efficient review by cardiologists and significantly reducing the time
spent analyzing ECG recordings. Distinct from consumer devices that offer
ECG recording, Viscero provides high-fidelity, continuous monitoring over
extended periods, capable of spanning weeks or months. This innovation
marks a significant leap in wearable healthcare technology, presenting a
practical, non-invasive solution for long-term heart monitoring.

Minimally Invasive Injectable Electrode Could Revolutionize Neuromodulation Pain Treatment

T
he primary approach to pain management often includes corti-
costeroid drug injections, delivered using needles ranging from
18-23 gauge. These injections provide pain relief lasting from
a few weeks to several months. However, their use is restricted to 2-4
times a year due to possible side effects like tissue weakening and hyper-
glycemia. If the intervals between treatments are surpassed, doctors may
explore other options such as alternative medications, radiofrequency
ablation, surgery, or neuromodulation. Now, a minimally invasive inject-
able electrode minimizes or eliminates the need for surgery, as well as
more drug injections or oral drugs for pain management. Once implant-
ed, this device establishes a low-impedance pathway for electrical signals
to travel from just below the skin to the nerve responsible for pain
transmission, all without requiring sutures or leaving any visible scars.
Neuronoff, Inc. (Cleveland, OH, USA; www.neuronoff.com) has
developed the Injectrode, a groundbreaking device for peripheral nerve
stimulation and a pioneer in minimally invasive transcutaneous stimu-
lation. This technology offers a simple treatment alternative for chronic
pain sufferers while avoiding the need for medications or invasive surger-
ies. The Injectrode is designed as an easy-to-place, long-term lead that re-
mains virtually undetectable externally, maintaining patient privacy. The
aesthetic results of a completely injected lead without any external wires
or protrusions mark a significant improvement over current offerings.
Neuronoff has recently achieved a significant milestone in chronic
pain treatment by successfully conducting the first human implant of
the Injectrode. This development is poised to transform chronic pain
management by offering a less invasive, transcutaneously stimulated
option compared to traditional neuromodulation therapies. In this land-
mark study, two participants underwent the minimally invasive proce-
dure, with the injectable electrode targeting peripheral nerve branches
in the lumbar lower back, an important site for novel lower back pain
treatments. This accomplishment represents a major step forward in
minimally invasive neuromodulation therapies. The initial human trial
highlights the Injectrode's ability to effectively target nerve sites with
minimal or no unintended muscle activation, offering a new option for
treating chronic lower back pain.
"The ease of placement of the Injectrode in this initial study is in-
credibly promising," said principal investigator Dr. Amol Soin who led
the study. "This simple needle-based approach is poised to give patients
and physicians a viable early treatment option that isn't a steroid injec-
tion or pharmacological solution."
"This successful start of our lumbar peripheral nerve stimulation
study marks a significant milestone for Neuronoff,” said Manfred Fran-
ke, CEO of Neuronoff. “It represents a major step toward our goal of
reducing the barriers to entry for neuromodulation-based treatments
by addressing the common patient concern about the surgery often
required for chronic neuromodulation.”
HospiMedica International
February-March/2024 14
 Critical
To view this issue in interactive digital magazine format visit www.HospiMedica.com
Care

AI Algorithm Monitors Vital Signs

to Detect Sepsis Before Symptoms
Cont’d from cover
Algorithms designed to aid early sepsis recognition could potentially en-
hance patient outcomes, yet there is limited research on their real-world
impact.
At UC San Diego Health (San Diego, CA, USA; www.health.ucsd.
edu), researchers have developed an AI model named COMPOSER to
rapidly identify patients at risk of sepsis. This model leverages real-time
data to predict sepsis before clear clinical signs emerge. Operating
discreetly, COMPOSER continually monitors each patient from the
moment they enter the emergency department, analyzing over 150
variables linked to sepsis, including lab results, vital signs, medications,
demographics, and medical history. The advanced AI algorithms in
COMPOSER can detect subtle patterns not immediately apparent to
clinicians. By evaluating these risk factors, the system generates highly
accurate sepsis predictions. Image: The AI surveillance tool successfully helps to predict sepsis
Should a patient exhibit a combination of high-risk factors for sepsis, (Photo courtesy of UC San Diego Health)
COMPOSER alerts the nursing staff through the hospital’s electronic patient outcomes through an AI deep-learning model.
health record. The nurses then collaborate with physicians to decide the “It is because of this AI model that our teams can provide life-saving
best course of action. If the algorithm determines that the risk patterns are therapy for patients quicker,” said study co-author Gabriel Wardi, MD,
more likely attributed to other conditions, it does not send an alert. Since chief of the Division of Critical Care in the Department of Emergency
its activation in December 2022, COMPOSER has been implemented in Medicine at UC San Diego School of Medicine. The study was published
various in-patient units at UC San Diego Health. A study involving over online in npj Digital Medicine on January 23, 2024.
6,000 patient admissions before and after deploying COM-
POSER in UC San Diego Medical Center and Jacobs Medical
Center emergency departments revealed a 17% reduction in
mortality, marking the first reported instance of improved

Wearable Sensor Accurately

Measures Biomarker Concentrations
in Sweat Samples

S
kin-applied sensors are emerging as a non-in-
trusive, affordable method for detecting vital
biomarkers in sweat, aiding clinicians in making
prompt and precise diagnoses. However, until now, these The Leading April
sensors could only identify the presence of biomarkers and Medical Fair 25-27,
struggled with accurately detecting their concentrations
due to the sporadic and unpredictable nature of sweat in Eurasia 2024
production. To address this challenge, a team of scientists
has introduced a sensor that precisely measures biomarker
concentrations in sweat samples.
The research team from Penn State (University Park,
PA, USA; www.psu.edu) designed a dual-channel sensor
for capturing sweat. One channel is tasked with mea-
suring the biomarker level, while the other assesses the
sweat volume. This sensor employs a dye that reacts to
the presence of the biomarker and produces a visible
indication, allowing for a simple, equipment-free reading.
This feature makes the sensor particularly beneficial in
remote settings where advanced technological resources
may be scarce. Detecting the concentration of a biomark-
er is critical for accurate diagnostics. For instance, the
team has proposed their sensor's application in diagnosing
conditions like cystic fibrosis, typically characterized by Scan the
QR code for more
elevated chloride levels in the patient. information!
“The typical course of action to diagnose cystic fibrosis
is to induce a local sweat through exercise, but with our
sensor, we can detect the chloride concentration in sweat
without requiring the patient to exercise, since we can use
passive heat-induced sweating with our wearable form of
the testing setup,” said Huanyu “Larry” Cheng, the James www.expomedistanbul.com @expomedeurasia

L. Henderson, Jr. Memorial Associate Professor of Engi-

neering Science and Mechanics at Penn State.

15 HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

PHLEBOTOMY 5-DRAWER CART INTRAVASCULAR TEMPERATURE ISOLATION STRETCHER

WATERLOO HEALTHCARE MANAGEMENT SYSTEM ZOLL MEDICAL SAVION INDUSTRIES

The MTWA-34696-WHT tall phlebotomy 5-drawer cart
is built to minimize trips back to the lab for fresh sup-
plies. The all-in-one cart’s unique
design allows it to be utilized as an
IV cart, suture cart, and more.
The Thermogard HQ intravascular temperature man-
agement system streamlines the path to high-quality
temperature management with en-
hanced data insights and improved
setup features.
The IS 736 isolation stretcher features a carbon filter
and blower for full air circulation within the chamber. It
comes with rechargeable batteries
allowing full mobility of the units
for up to 10 hours of continuous
operation.

LINKXPRESS COM HMI-03-24 216 LINKXPRESS COM HMI-03-24 217 LINKXPRESS COM HMI-03-24 218

Fully Implantable, Wirelessly Charged Device Treats

Recurrent or Refractory Ascites Due to Liver Cirrhosis

R
ecurrent and refractory ascites is a key complication of liver
cirrhosis, characterized by the accumulation of fluid in the abdo-
men. These patients can have up to 15 liters of extra fluid in their
bodies, causing many health issues and severely impacting their daily lives.
Although diuretics are the standard of care, the problem is that in many
patients they are no longer effective and/or tolerable, requiring patients to
undergo regular paracentesis. Paracentesis is a painful and burdensome pro-
cedure that drains ascites from the abdomen using a large needle over an
extended period, with only short-term benefits for the patients, requiring
frequent hospitalizations and severely impacting their quality of life. Now,
a fully implantable, wirelessly charged device for patients with recurrent or
refractory ascites due to liver cirrhosis could transform the lives of these
patients by virtually eliminating the need for paracentesis and delivering
clinically important improvements in quality of life.
Sequana Medical’s (Ghent, Belgium; www.sequanamedical.com)
alfapump automatically and continuously removes ascites from the
abdomen into the bladder, where it is naturally eliminated through uri-
nation. Sequana has submitted a Premarket Approval (PMA) application
to the US Food and Drug Administration (FDA) for alfapump which
could become the first active implantable medical device in the US for
treating liver ascites upon approval. The PMA filing is based on the
successful execution of Sequana’s pivotal POSEIDON study, a landmark
study across 18 centers in the US and Canada with a total of 69 patients
implanted with the alfapump. The primary effectiveness endpoints Image: Pending FDA approval, alfapump could become the first active
implantable medical device in the US for treating liver ascites (Photo
at six months post-implantation in the Pivotal Cohort exceeded the
courtesy of Sequana Medical)
predefined thresholds with statistical significance, and primary safety
endpoint data was in line with expectations. a seamless and thorough review process intended to bring our break-
Data at 12 months post-implantation continued to show a strong and through device to the US market as soon as possible.”
durable clinical profile, virtually eliminating the need for therapeutic “This is a key milestone for the alfapump and underscores our com-
paracentesis and delivering a clinically meaningful improvement in mitment to improving treatment options for patients with recurrent or
patients’ quality of life. Data from the patient preference study and a refractory liver ascites,” said Ian Crosbie, Chief Executive Officer of
matched cohort analysis of the NACSELD registry with the POSEIDON Sequana Medical. “This overlooked patient group is forecast to grow
Pivotal Cohort indicated that US patients have a strong preference for strongly due to NASH / MASH and today’s limited treatment options
the alfapump vs. standard paracentesis procedures and that the safety often lead to poor clinical outcomes, severely reduced quality of life, a
profile of the alfapump is comparable to standard of care. substantial burden on their caregivers and high costs to payors. Data
“The submission of our Premarket Approval application to the FDA from our North American pivotal study demonstrate the potential for
is the result of an enormous team effort and a clear demonstration of alfapump to transform the lives of these patients by virtually eliminating
our intensive preparation to fulfil US regulatory requirements,” said the need for paracentesis and delivering clinicially important improve-
Timur Resch, Global Vice President QM/QA/RA at Sequana Medical. ments in quality of life. We anticipate FDA approval in the second half
“We have great confidence in the strength of our PMA submission and of 2024 and look forward to introducing the alfapump through our own
look forward to work in close collaboration with the FDA to facilitate specially sales force focused on US liver transplant centers.”

HospiMedica International
February-March/2024 16
 Surgical Imaging Module Offers
Enhanced Real-Time Insights

D
uring surgeries, identification of critical structures and as- marked ActivSight de-
sessment of tissue perfusion are vital for providing patients vice’s LSCI.
with the best possible chance of healing well without facing “As we continue to
life-threatening or expensive complications. Now, an intraoperative achieve significant mile-
imaging module provides enhanced visualization and real-time, on-de- stones such as this, our
mand surgical insights in the operating room while seamlessly attaching vision is to transform
to today’s laparoscopic and robotic systems as well as integrating with the collective surgical
standard monitors. experience by leveraging
Activ Surgical’s (Boston, MA, USA; www.activsurgical.com) Activ- emerging technologies
Sight Intelligent Light is an easy-to-adapt module that is transforming and data into insights
the operating room by seamlessly upgrading existing operating room that make cutting-edge
equipment while serving as the “eyes” of their cutting-edge platform. surgery accessible for
The hardware-agnostic imaging module is designed to provide surgeons all,” said Manisha Shah-
with real-time intraoperative visual data and imaging not presently Bugaj, Chief Executive
available to surgeons through existing technologies. With ActivSight, Officer at Activ Surgical.
surgeons can access critical intraoperative visual data as augmented
reality overlays, helping to increase surgical outcomes and patient safety. Image: The ActivSight device is 510(k)-cleared and CE-marked (Photo
More informed real-time decisions during surgery using intelligent visu- courtesy of Activ Surgical)
alization technology means potentially fewer complications and tissue
injuries promising better clinical outcomes. RS
TO LY
IBU PP
A recent clinical study demonstrated that ActivSight’s Laser Speckle I S TR TO A
D TED
I
Contrast Imaging (LSCI) provides real-time, repeatable, and on-demand INV
perfusion assessment without dyes to help prevent esophageal anasto-
motic leaks. Attributed to inadequate tissue perfusion or excess tension, YOUR GLOBAL SOURCE FOR STERILIZATION ACCESSORIES
esophageal anastomotic leaks are among the most feared in gastrointes-
THERMO
tinal surgery. Real-time intraoperative perfusion assessment can identify
RESISTANT
perfusion deficits to help prevent leaks. The study saw the completion
GLOVES
of the first international procedure using the 510(k)-cleared and CE-
Up to 37 cm
in length
Bioengineered Material Rapidly
Stops Bleeding During Surgery in STERILIZABLE INSTRUMENT
& WORK-SURFACE MATS
Patients on Blood Thinners Thermo-Resistant (-60 °C to 300 °C) TURBO WASHING
MACHINES TRAYS
Fully Washable & Flexible

A
nticoagulation and antiplatelet medications like heparin or Suitable for central sterilization services
aspirin, commonly taken by millions worldwide to treat heart Sterilizable Heavy Silicone Cover & Transport Tablet
attack and stroke, also elevate the risk of potentially fatal
bleeding during injuries or surgeries. Globally, over five million people SILICON INSTRUMENT MAT MICRO INSTRUMENT MAT
die annually from trauma, with more than a third of these deaths due to Front Back
uncontrolled bleeding. Now, researchers have created a porous material
that significantly absorbs blood and effectively initiates clotting, even in
patients on these medications. Remarkably, this new hemostat managed
to stop bleeding in an average of about five minutes in cardiac catheter- WASHING TRAYS MAT WASHING TRAYS MAT
ization patients on anticoagulants, marking a substantial improvement
from the lengthy traditional compression methods that can take more
than two hours.
The research team, led by investigators from Brigham and Women’s Front Back Front Back

Hospital (Boston, MA, USA; www.brighamandwomens.org), developed

a more effective hemostat by employing a “rational engineering” ap- NEW!
proach. They simulated blood flow through various pore structures,
drawing inspiration from the lung’s alveoli – spherical air sacs with a
large surface area and a complex porous structure that enable efficient SILICONE
TABLET
blood interaction. This guided them to design their material with a Exchangable Net
AND STEEL
similar intricate, spherical microporous structure, optimizing blood ab- COVER NETS
sorption and the accumulation of vital clotting components like platelets.
Chitosan, a substance extracted from shellfish, forms the base of this STERILIZABLE
WORK-SURFACE MATS
alveoli-like structure. Already utilized in some hemostats, chitosan’s
positive charge effectively attracts negatively charged platelets and Exchangable Nets 100% Silicone Size: 2400 x 1200 mm (3 mm thick)
fibrinogen, key blood clot components. The researchers discovered an
additional benefit: chitosan activates the TLR-2 clotting pathway, direct- VICOTEX S.A.

ly stimulating clotting even in patients on anticoagulants. When tested Place de la Gare 1 • 1009 Pully • Switzerland
Tel: (41) 21-728-4286 • Fax: (41) 21-729-6741
on 70 patients undergoing cardiovascular catheterization and on hepa- E-Mail: contact@vicotex.com
rin, the material reduced bleeding to an average stoppage time of about www.vicolab.com
Cont’d on page 18

LINKXPRESS COM HMI-03-24 117

17 HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

COMPACT HYSTEROSCOPY SYSTEM OPERATING CEILING LED LIGHT MOBILE LITHOTRIPTER (SWL)
XION MEDICAL UZUMCU STORZ MEDICAL

The EndoDESK Spectar is a compact hysteroscopy
system for diagnostics and outpatient surgery that
features an integrated high-perfor-
mance LED light source and offers
excellent image quality.
The DL-66CM operating ceiling LED light has two
light heads with 160,000 lux light power along with a
24” Active Matrix TFT LCD medical
monitor with 1920 x 1200 resolution
added to the lamp.
The MODULITH SLK intellect is a flexible and mobile
lithotripter (SWL) that can be combined with various
modular components such as C-
arcs and patient tables. It features
the proven STORZ MEDICAL cylin-
drical shock wave source.

LINKXPRESS COM HMI-03-24 219 LINKXPRESS COM HMI-03-24 220 LINKXPRESS COM HMI-03-24 221

AI Predicts Death and Complications in

Angioplasty and Stent Patients

P
ercutaneous coronary intervention (PCI) is a minimally
invasive procedure used to treat blocked heart arteries. Tradi-
tionally, during PCI, blocked arteries are cleared by inflating
a balloon and potentially inserting a stent to enhance blood flow from
the heart. Although this procedure is less risky than open-heart surgery,
it can still lead to complications such as bleeding and kidney injury.
Recognizing these risks, a team of researchers has developed a new
AI-powered algorithm that can accurately predict mortality and compli-
cations following a PCI. This innovative tool holds promise for aiding
clinicians in making more informed treatment decisions.
Several risk stratification tools have been developed to identify
risk after PCI, although most are modestly accurate and were created
without involving patients. The research team at Michigan Medicine
(Ann Arbor, MI, USA; www.uofmhealth.org) set out to develop a more
accurate risk stratification tool, incorporating patient data into the de-
sign process, unlike previous models. The research team gathered com-
prehensive data on all adult patients who underwent PCI from April
2018 to the end of 2021. This data was sourced from the Blue Cross
Blue Shield of Michigan Cardiovascular Consortium (BMC2) registry, a
network of hospitals throughout Michigan that uses collective data to
enhance care quality and patient outcomes.
Utilizing over 20 pre-procedural characteristics, including factors
like age, blood pressure, and total cholesterol, the team employed
the machine learning software "XGBoost" to construct a risk predic-
tion model. This AI-driven algorithm demonstrated high accuracy in
predicting deaths, major bleeding events, and the necessity for blood
transfusions, surpassing other models that used similar pre-procedural
characteristics. To make this advanced technology widely accessible, it
has been integrated into both computer and phone applications, avail-
able for free use. This development represents a significant step forward
in improving clinical decision-making for patients undergoing PCI.
"Precise risk prediction is critical to treatment selection and the
shared decision-making process,” said lead David E. Hamilton, M.D.,
a cardiology-critical care fellow at Michigan Medicine. “Our tool can
recognize a wide array of outcomes after PCI and can be used by care
providers and patients together to decide the best course of treatment."
"In the age of widespread smartphones and electronic medical re-
cords, this computerized risk score could be integrated into electronic
health systems and made easy to use at the bedside,” added senior
author Hitinder Gurm, MBBS, interim chief medical officer at U-M
Health. “It would not only help relay complex information to the pro-
vider quickly, but it could also be used to enhance patient education on
the risks related to PCI."

Bioengineered Material Rapidly Stops Bleeding During Surgery in Patients on Blood Thinners
Cont’d from page 17
five minutes for low-dose heparin patients, and under nine minutes for
those on up to 12,500 IU heparin doses.
The chitosan pad simplifies application and removal compared to
traditional gauze, which often requires long, strong compression and
can be painful and risky to remove. The chitosan hemostat, being
more absorptive, can be removed more cleanly and comfortably from
wounds. The research team is now exploring further advancements,
including studying the wound healing process post-application of the
chitosan hemostat and developing next-generation wound dressings
capable of drug delivery or enhancing wound cleanliness, potentially
reducing the frequency of dressing changes.
“This is a next-generation hemostat that effectively stops bleeding,
even in patients who take anticoagulation or antiplatelet medications,”
said corresponding author Hae Lin Jang, Ph.D., of the Center for Engi-
neered Therapeutics. “We used an exciting, interdisciplinary approach
that combines engineering principles, materials science, and under-
standings of molecular biology to overcome the limitations of existing
therapies and address a real clinical need.”
“This hemostat can save valuable time in emergency situations,”
added first author Vivian K. Lee, PhD, of the Center for Engineered
Therapeutics. “In emergencies, it can be extremely challenging to
screen the prescription information of a patient to provide appropriate
anticoagulation reversal therapy to patients on anticoagulants. If a he-
mostat can bypass a medication’s anticoagulating mechanisms, it can
be used in a wide range of patients, saving time, and potentially saving
lives.” The research team’s findings were published in the journal PNAS
on January 22, 2024.
HospiMedica International
February-March/2024 18
 To view this issue in interactive digital magazine format visit www.HospiMedica.com
Surgical
Techniques

Replacement Valve That Grows Inside

Body to Revolutionize Heart Treatment

H
eart valve replacement surgery, a life-saving procedure, has
been available for over six decades. However, it comes with
significant medical limitations, whether the valves used are
mechanical or biological. Patients with mechanical heart valves need
lifelong medication to prevent blood clotting. Biological valves, in con-
trast, have a lifespan of only 10 to 15 years. The situation is even more
complex for children with congenital heart defects, as their growing
bodies necessitate multiple valve replacements before they reach adult-
hood. Now, recent research suggests that the natural repair mechanisms
in humans can be leveraged to build a living heart valve that grows
inside the body along with the patient.
The new approach developed by researchers at Imperial College Image: Inside the Agilent Measurement Suite at Imperial’s Molecular Sci-
London (London, UK; www.imperial.ac.uk) involves a procedure ences Research Hub (Photo courtesy of Imperial College London)
that begins with a nanofibrous polymeric valve created from a Although currently focused on heart valve replacement, this technology
biodegradable polymer scaffold, unlike the durable plastic that is has potential applications in other areas, such as treating vascular condi-
typically used. Once implanted, this scaffold recruits cells and guides tions, repairing blood vessels damaged by dialysis, and creating cardiac
their development, turning the body into a bioreactor for new tissue patches for heart repair.
growth. Over time, the scaffold is naturally replaced by the body’s “The aim of the concept we’ve developed is to produce a living valve
own tissues. At the heart of this innovation is the scaffold material, in the body, which would be able to grow with the patient,” said Dr. Yu-
designed to attract, house, and direct the patient’s cells, thereby en- an-Tsan Tseng, a biomaterials scientist. “Once you have the scaffold, it be-
couraging tissue growth while preserving valve functionality. comes a platform technology that you can use to engineer other tissues.”
The research team conducted
laboratory validation studies and
reported the initial results from an-
imal tests. The valves, transplanted
into sheep, were observed for up PREMIER MULTIMEDIA PLATFORM
to six months. They functioned SERVING THE WORLD’S
effectively throughout this period
and demonstrated promising cellu- HOSPITAL / MEDICAL COMMUNITY
lar regeneration. Notably, the study
highlighted the scaffold’s ability to Anytime, Anywhere, On the Go...
attract blood cells that transform in-
to functional tissues through a pro-
cess known as endothelial-to-mes- PRINT MAGAZINE
enchymal transformation (EndMT).
Additionally, nerve and fatty tissue INTERACTIVE
growth within the scaffold was ob- DIGITAL EDITION
served, mirroring what one would
WEB PORTAL
expect in a normal valve. Concur-
ENGLISH • SPANISH
rently, the polymer scaffold un-
derwent degradation, paving the
way for new tissue growth. This
degradation was monitored using
gel permeability chromatography
(GPC) at the Agilent Measurement
Suite (AMS) in Imperial’s Molecular
Sciences Research Hub in White
City, which is equipped with so-
phisticated analytical tools.
Further research is needed to
fully understand the mechanisms
behind the polymer’s degradation
and its correlation with tissue
regeneration. The next phase in- MOBILE
volves extending animal studies to VERSION
monitor tissue regeneration over .com
DAILY CLINICAL NEWS

longer periods. This data will be vi-

tal for obtaining regulatory approval
for the first human clinical trials,
expected within the next five years. ­­PRINT MAGAZINE • INTERACTIVE DIGITAL EDITION
Additionally, refining the manufac- WEB PORTAL • MOBILE VERSION • MOBILE APPS
turing processes of the valves is HOSPIMEDICA EXPO • E-NEWSLETTER
necessary. As the project progresses, E-MAIL MARKETING • ONLINE SOLUTIONS
the team plans to seek commercial
partners for later-stage clinical trials.

19 HospiMedica International
February-March/2024
WORLD’S MEDICAL DEVICE MARKETPLACE

To receive prompt and free information on products, log on to

www.linkXpress.com or scan the QR code on your mobile device

4K ENDOSCOPIC SURGICAL MONITOR INTRAVENTRICULAR NEUROENDOSOPIC ELECTROSURGICAL UNIT

BEACON DISPLAY TECHNOLOGY SYSTEM BRAUN, B. BOWA

S3285P is a high-performance 4K endoscopic surgi-
cal medical monitor specially designed for operating
rooms with the characteristics of high
brightness, high contrast, and wide
viewing angle.
MINOP is an intraventricular neuroendosopic system
designed primarily for the treatment of intraventricular
indications such as occlusive hydro-
cephalus and the removal of tumors
and cysts.
The ARC 250 electrosurgical unit offers all basic
electrosurgical functions in combination with the latest
control technology. It is designed for
use in various specialty areas and
wide range of applications.

LINKXPRESS COM HMI-03-24 222 LINKXPRESS COM HMI-03-24 223 LINKXPRESS COM HMI-03-24 224

Surgical Guidance System Targets Tumor Location in

Multiple Dimensions for Precise Excision

E
very 14 seconds, a woman receives a breast cancer diagnosis,
making it the world’s most prevalent cancer. In 2020 alone,
2.3 million women were diagnosed, and 685,000 succumbed
to the disease. Lumpectomy, a breast-conserving surgery, is a common
treatment option. Yet, approximately 20-30% of women who undergo
this procedure require a second surgery. Now, a new surgical guidance
system targets tumor location in multiple dimensions for precise ex-
cision and successful surgeries, marking a significant advancement in
breast cancer care.
The SCOUT MD Surgical Guidance System from Merit Medical
Systems (South Jordan, UT, USA; www.merit.com) is a groundbreaking
solution that allows for the implantation of up to four different reflector
configurations in abnormal breast tissue or other soft tissues. This enables
precise localization of tumors in multiple dimensions, aiding in more
accurate surgical excision. Physicians and patients have the option to im-
plant the reflector during a biopsy, and its long-term implant can be done
any time before the surgery. The reflector, with a body size of just 4mm
- smaller than a grain of rice – features antennas made of super-elastic niti-
nol alloy, a material frequently used in medical devices. It offers a real-time
distance measurement capabil-
ity within a 60mm range and
360-degree detection with an
accuracy of ± 1mm.
The system offers flexi-
bility in placement methods,
including ultrasound, radiography, and stereotactic guidance. The
SCOUT Guide activates the previously passive reflector, providing
instant feedback to guide the surgical dissection path and reduce
guesswork. This precise method aims to minimize harm to surrounding
healthy tissue, decrease the chances of needing a second operation, and
prevent the emotional and physical distress often associated with repeat
surgeries. The SCOUT MD Surgical Guidance System has received
510(k) clearance from the US Food and Drug Administration (FDA),
expanding Merit’s oncology portfolio aimed at improving the diagnosis
and treatment of breast cancer and other soft tissue cancers.
Image: Using the SCOUT system, surgeons can precisely target the affected
tissue to pinpoint its location within 1mm (Photo courtesy of Merit Medical)

Blood-Brain-Barrier Opening Device Enhances Chemotherapy Drug Delivery to Brain Tissue

T
he blood-brain barrier (BBB) presents a significant challenge
in treating gliomas, a type of diffuse tumor that infiltrates the
peri-tumoral normal brain. This barrier prevents over 95% of
small-molecule drugs and all large-molecule drugs from entering the
brain, thus reducing their therapeutic impact. Now, an implantable
device utilizes the power of pulsed ultrasound to temporarily open the
BBB. This provides a window period during which drug therapies can
be administered and can reach the brain in higher and more effective
concentrations when the BBB is disrupted.
Carthera’s (Lyon, France; carthera.eu) SonoCloud device is designed
to be implanted in a skull window beneath the skin, remaining invisible
from the outside. When activated for a few minutes via a transdermal
needle connected to an external control unit, the device employs low
intensity pulsed ultrasound (LIPU) to breach the BBB for several hours.
This window of opportunity allows for the administration of drug ther-
apies. The concept of using LIPU to disrupt the BBB has been under
pre-clinical development for over two decades. The technology leverag-
es low-intensity ultrasound, akin to levels used in diagnostic imaging,
in conjunction with an intravenous microbubble agent to stimulate a
therapeutic effect. The LIPU causes the injected microbubbles in brain
microvessels to vibrate, mechanically disrupting the BBB’s tight junc-
tions, enhancing active transport across the BBB, and reducing active
drug efflux transporters.
Carthera has developed multiple versions of the SonoCloud device,
including SonoCloud-1 and SonoCloud-9. These MRI-compatible devic-
es are engineered to disrupt large regions of the BBB, aiming to improve
the therapeutic efficacy of drugs in specific brain areas. Currently, these
devices are undergoing clinical trials for glioblastoma, brain metastases,
and Alzheimer’s Disease. Carthera has initiated the SONOBIRD clinical
trial, an open-label, comparative, randomized, multicenter study with a
two-arm design and a 1:1 ratio. This trial will assess the overall survival
of glioblastoma patients treated with carboplatin chemotherapy in con-
junction with the SonoCloud-9 system to breach the BBB. Outcomes
will be compared against standard regimens recommended by medical
consensus, such as lomustine or temozolomide. Additionally, the trial
aims to evaluate the effectiveness of the SonoCloud-9 and carboplatin
treatment in delaying or reducing tumor growth.
“The launch of the SONOBIRD trial is a significant achievement in
the clinical development of the SonoCloud-9 system. If the efficacy of
carboplatin in combination with our device is proven, it will change the
paradigm of how we treat glioblastoma,” said Carole Desseaux, chief
clinical officer at Carthera.
HospiMedica International
February-March/2024 20
 To view this issue in interactive digital magazine format visit www.HospiMedica.com
Industry
News

International Hospital Federation

Announces 2023 IHF Award Winners
Cont’d from cover
The Awards Committee, comprising health leaders from across
the world and chaired by Dr Lawrence Lai, IHF Honorary Member,
received more than 500 entries from 43 countries and territories –
marking a record since the establishment of the Awards in 2015.
The IHF Awards 2023 recipients in each category are as follows:

..
Dr Kwang Tae Kim Grand Hospital Award:
Gold: Sheikh Shakhbout Medical City (United Arab Emirates).

..
Silver: King Faisal Medical Complex in Taif (Saudi Arabia).
Bronze: Apollo Cancer Centres (India).
Honorable mentions: Al Qassimi Women and Children Hospital
(United Arab Emirates), Avenue Healthcare (Kenya), King Khalid
Alkharj Hospital, Riyadh 1st Health Cluster (Saudi Arabia), French
Medical Institute for Mothers and Children (Afghanistan), Prince Image: The IHF Awards promote exchange of good practices in areas
Mohammed bin Abdulaziz Hospital (Saudi Arabia).

..
of healthcare leadership, environmental sustainability, and innovation
Seddiqi Holding Excellence Award for Corporate Social Responsibility:

.
(Photo courtesy of IHF)
Gold: Myongji Hospital (Republic of Korea).

.Silver: The Nairobi Hospital (Kenya).

Bronze: Al Amal Psychiatric Hospital (United Arab Emirates), and
.
Silver: Vicente Sotto Memorial Medical Center (Philippines), and
Apollo Multispeciality Hospitals, Kolkata (India).
.
Yale New Haven Health System (United States of America).
Honorable mentions: French Medical Institute for Mothers and
Bronze: Saudi German Health (Egypt), Samsung Medical Center
(Republic of Korea), and Emirates Health Services (United Arab
Children (Afghanistan), Manila Doctors Hospital (Philippines),
Lusiadas Saúde (Portugal), Amiri Medical Complex (Afghanistan),
Mediker LLP (Kazakhstan).
.
Emirates).
Honorable mentions: Emirates Health Services (United Arab
Emirates) Intelligence program for healthcare decisions, Jubail Gen-
..
Ashikaga-Nikken Excellence Award for Green Hospitals:
Gold: Oulu University Hospital (Finland).
eral Hospital (Saudi Arabia), Children’s Wisconsin (United States
of America), Apollo Proton Cancer Centre (India), Lusíadas Saúde
.Silver: Mediclinic Welcare Hospital (United Arab Emirates).
Bronze: Dubai Health Authority – Dubai Academic Health Corpo-
(Portugal).
American College of Healthcare Executives

.
ration (United Arab Emirates).
Honorable mentions: Aga Khan University (Pakistan), Emirates ..
Excellence Award for Leadership and Management:
Gold: Matosinhos Local Health Unit – ULSM (Portugal).
Health Services (United Arab Emirates), Sharm El-Sheikh Inter-
national Hospital (Egypt), Royal Hospital (Oman), Insel Gruppe
(Switzerland), Cleveland Clinic Abu Dhabi (United Arab Emirates),
..
Silver: Royal Hospital (Oman).
Bronze: Dubai Health Authority (United Arab Emirates).
Honorable mentions: Al-Kharj Maternity and Children Hospital
Performance and Digital Health, EHS (United Arab Emirates). (Saudi Arabia), Emirates Health Services (United Arab Emirates),
Sultanate of Oman Excellence Award SEHA Kidney Care (United Arab Emirates), Karolinska University
.
for Health Services During Crisis:
Gold: Tondo Medical Center (Philippines), and Hope Field Hospi-
Hospital (Sweden), Henry Ford Health (United States of America).

.
Mastercard Excellence Award for Quality and Patient Safety:

..
tal for Women and Children of Bangladesh (Bangladesh).
Silver: Sheba Medical Center (Israel).
Bronze: LUX MED (Poland), Eka Kotebe General Hospital (Ethi- ..
Gold: Fundació de Gestió Sanitària Hospital de la Santa Creu i
Sant Pau (Spain)
Silver: Hopitaux Universitaires de Genève (Switzerland)
opia), and Mariano Marcos Memorial Hospital and Medical Center

.
(Philippines).
Honorable mentions: People’s Hospital 115 (Vietnam), Apollo
Health & Lifestyle Limited (India), Predisan Health Ministry (Hon-
duras), Mariano Marcos Memorial Hospital and Medical Center
(Philippines).
American Hospital Association Excellence
.
Award for Healthcare Workers’ Wellbeing:
Gold: Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foun-
dation (Taiwan), and Alder Hey Children’s NHS Foundation Trust
(United Kingdom).
.Bronze: Tan Tock Seng Hospital (Singapore).
Honorable mentions: Health Information Systems – Emirates
Health Services (United Arab Emirates), Fujairah Hospital (United
Arab Emirates), Jubail General Hospital (Saudi Arabia), Al Qassi-
mi Hospital (United Arab Emirates), Cleveland Clinic Abu Dhabi
(United Arab Emirates), Tawam Hospital (United Arab Emirates),
King Saud Medical City (Saudi Arabia), China Medical University
Hospital (Taiwan), Emirates Health Services (United Arab Emirates).
The IHF Awards 2024 will be awarded at the 47th World Hos-
pital Congress to be held in Rio de Janeiro (Brazil), and the call for
entries will be announced in February 2024.

M&A Briefs
Mindray (Shenzhen, China; www.mindray.com) is to acquire con-
trol of APT Medical (Shenzhen, China; www.aptmed.com), a cardio-
vascular device company. The acquisition aims to merge the expertise
of both Mindray and APT Medical in the field.
Olympus Corporation (Tokyo, Japan; www.olympus-global.
com) acquired Taewoong Medical Co., Ltd. (Seoul, Korea; www.
taewoongmedical.com). Taewoong will join Olympus’ Therapeutic
Solutions Division, expanding Olympus's offerings in the GI market.
Karl Storz (Tuttlingen, Germany; www.karlstorz.com), acquired
Innersight Labs Ltd. (ISL, London, UK; www.innersightlabs.
com), a software manufacturer, continuing its expansion into inno-
vative software solutions.
Medical Illumination International (Chatsworth, CA, USA;
www.medillum.com) acquired IsoLux (Naples, FL, USA; www.
isoluxllc.com). The acquisition of IsoLux, known for its innovative
surgical headlight products, is set to expand Medical Illumination's
portfolio in surgical and medical lighting solutions.
Stryker (San Jose, CA, USA; www.stryker.com) is to acquire SERF
SAS (Décines-Charpieu, France; www.serf.fr), a joint replacement com-
pany. The acquisition is expected to strengthen Stryker's presence in
France and across Europe, as well as expand its global joint replacement
portfolio.

21 HospiMedica International
February-March/2024
International
Calendar
For a free listing of your event,
or a paid advertisement in this section, contact:
International Calendar, HospiMedica International
E-mail: info@globetech.net
2024
MARCH
ICE 2024 – 21st International Congress of
Endocrinology. Mar 1-3; Dubai, UAE;
icecongress.com
CRITICARE 2024 – 30th Annual Conference
of the Indian Society of Critical Care Medi-
cine (ISCCM). Mar 1-3; Kolkata, India;
criticare.isccm.org
WCA 2024 – 18th World Congress of Anaes-
thesiologists. Mar 3-7; Singapore; wca2024.
org
5th MedExpo Ethiopia 2024. Mar 6-8; Ad-
dis Ababa, Ethiopia; expogr.com/ethiopia/
medexpo
ESGO 2024 – 25th European Congress on
Gynaecological Oncology. Mar 7-10; Barcelo-
na, Spain; congress.esgo.org
HIMSS24 - Healthcare Information and
Management Systems Society. Mar 11-15;
Orlando, FL, USA; himss.org
EMIM 2024 – 19th European Molecular Im-
aging Meeting. Mar 12-15; Porto, Portugal;
e-smi.eu
Medical Fair India 2024. Mar 13-15; Mum-
bai, India; medicalfair-india.com
51st Annual Meeting of the Japanese Soci-
ety of Intensive Care Medicine (JSICM). Mar
14-16; Sapporo, Japan; jsicm.org
KIMES 2024 – Korea International Medical &
Hospital Equipment Show. Mar 14-17; Seoul,
Korea; kimes.kr
SALMED International Medical Fair 2024.
Mar 19-21; Poznan, Poland; salmed.pl
43rd ISICEM – International Symposium on
Intensive Care & Emergency Medicine. Mar
19-22; Brussels, Belgium; isicem.org
AOCR 2024 – Asian Oceanian Congress
of Radiology. Mar 22-25; Taipei, Taiwan;
aocr2024.org
SIR 2024 – Annual Meeting of the Society
of Interventional Radiology. Mar 23-28; Salt
Lake City, UT, USA; sirmeeting.org
APRIL
144th Annual Meeting of the American Sur-
gical Association (ASA). Apr 4-6; Washing-
ton, DC, USA; meeting.americansurgical.org
39th Annual EAU Congress – European As-
sociation of Urology. Apr 4-7; Paris, France;
uroweb.org
UltraCon 2024 – Annual Conference of the
American Institute of Ultrasound in Med-
icine (AIUM). Apr 6-10; Austin, TX, USA;
aium.org
37th Medicall Expo. Apr 6-8; Hyderabad,
India; medicall.in
ACC.24 – American College of Cardiology’s
73rd Annual Scientific Session & Expo. Apr
6-8; Atlanta, GA, USA; accscientificsession.
acc.org
83rd Annual Meeting of Japan Radiological
Society (JRS). Apr 11-14; Yokohama, Japan;
radiology.jp
WCO-IOF-ESCEO 2024 - World Congress on
Osteoporosis, Osteoarthritis and Musculo-
skeletal Diseases. Apr 11-14; London, UK;
wco-iof-esceo.org
CMEF Spring 2024 – 89th China Medical
Equipment Fair. Apr 11-14; Shanghai, China;
www.cmef.com.cn
WCN 2024 – World Congress of the Interna-
tional Society of Nephrology (ISN). Apr 13-
16; Buenos Aires, Argentina; theisn.org
AAN 2024 – 76th Annual Meeting of the
American Academy of Neurology. Apr 13-18;
Denver, CO, USA; aan.com
Medic West Africa 2024. Apr 17-19; Lagos,
Nigeria; medicwestafrica.com
SEACare 2024 – 24th Southeast Asian
Healthcare & Pharma Show. Apr 17-19; Kua-
la Lumpur; Malaysia; abcex.com
24th MEDEXPO Africa 2024. Apr 17-19; Nai-
robi, Kenya; expogr.com/kenyamed
SAGES 2024 – Annual Meeting of the Soci-
ety of American Gastrointestinal and Endo-
scopic Surgeons. Apr 17-20; Cleveland, OH,
USA; sages.org
124th Congress of the Japan Surgical Society
(JSS). Apr 18-20; Tokoname, Japan; jp.jssoc.
or.jp
DCK 2024 – 141st Congress of the German
Society for Surgery (DGCH). Apr 24-26;
Leipzig; Germany; dgch.de
KSCCM-ACCC 2024 – 44th Annual Con-
gress of the Korean Society of Critical
Care Medicine. Apr 24-26; Seoul, Korea;
accc.or.kr
Expomed Euroasia 2024. Apr 25-27; Istan-
bul, Turkey; expomedistanbul.com
AAEM24 – 30th Annual Scientific Assembly
of the American Academy of Emergency
Medicine. Apr 27 - May 1; Austin, TX, USA;
aaem.org
ECTES 2024 – 23rd Congress of the Euro-
pean Society for Trauma & Emergency
Surgery (ESTES). Apr 28-30; Lisbon, Portugal;
estes-congress.org
ECIO 2024 – European Conference on Inter-
ventional Oncology. Apr 28 - May 1; Palma
de Mallorca, Spain; ecio.org
MAY
APSC-ECS 2024 - 28th Asian Pacific Society
of Cardiology Congress & 15th Annual
Emirates Cardiac Society Congress. May 2-4;
Dubai, UAE; apsc-ecs2024.com
APSCVIR 2024 – 18th Annual Meeting of the
Asia Pacific Society of Cardiovascular and
Interventional Radiology. May 3-5; Bangkok,
Thailand; apscvir2024.com
AUA 2024 – Annual Meeting of the Amer-
ican Urological Association. May 3-6; San
Antonio, TX, USA; auanet.org
ESTRO 2024 – Annual Congress of the Euro-
pean Society of Radiology & Oncology. May
3-7; Glasgow, UK; estro.org
2024 ISMRM & ISMRT Annual Meeting
& Exhibition – International Society for
Magnetic Resonance in Medicine. May 4-9;
Singapore; ismrm.org
ARRS 2024 Annual Meeting – American
Roentgen Ray Society. May 5-9; Boston, MA,
USA; arrs.org
Vietnam Medi-Pharm 2024 - The 31st Viet-
nam International Medical and Pharmaceu-
tical Exhibition. May 9-12; Hanoi, Vietnam;
vietnammedipharm.vn
ECCC Dubai 2024 - 20th Emirates Critical
Care Conference. May 10-12; Dubai, UAE;
eccc-dubai.com
ECE 2024 – 26th Congress of the European
Society of Endocrinology. May 11-14; Stock-
holm, Sweden; ese-hormones.org
KIHE 2024 – 29th Kazakhstan International
Healthcare Exhibition. May 15-17; Almaty,
Kazakhstan; kihe.kz
ATS 2024 – International Conference of the
American Thoracic Society. May 17-22; San
Diego, CA, USA; conference.thoracic.org
Hospitalar 2024. May 21-24; Sao Paulo, Bra-
zil; hospitalar.com
EFORT Congress 2024 – 25th Annual Con-
gress of European Federation of National
Associations of Orthopaedics and Trau-
matology. May 22-24; Hamburg, Germany;
congress.efort.org
61st ERA Congress – European Renal As-
sociation. May 23-26; Stockholm, Sweden;
era-online.org
ASCVTS – 32nd Annual Meeting of the Asian
Society for Cardiovascular and Thoracic Sur-
gery. May 23-26; Wuhan, China; ascvts.org
EuroAnaesthesia 2024 – European Society
of Anaesthesiology. May 25-27; Munich,
Germany; euroanaesthesia.org
ESTS 2024 – 32nd Meeting of the European
Society of Thoracic Surgeons. May 26-28;
Barcelona, Spain; ests2024.com
92nd EAS Congress 2024 – European Athero-
sclerosis Society. May 26-29; Lyon, France;
eas-society.org
ESGAR 2024 – Annual Meeting of the Eu-
ropean Society of Gastrointestinal and Ab-
dominal Radiology. May 28-31; Gothenburg,
Sweden; esgar.org
JUNE
12th Congress of the World Federation of Pe-
diatric Intensive and Critical Care Societies. Jun
1-5; Cancun, Mexico; wfpiccs.org
India Health 2024. Jun 13-15; New Delhi, In-
dia; indiahealth-exhibition.com
EHA 2024 - Annual Congress of the European
Hematology Association. Jun 13-16; Madrid,
Spain; ehaweb.org
MedtecLIVE 2024. Jun 18-20; Stuttgart, Ger-
many; medteclive.com
CARS 2024 – Computer Assisted Radiology
and Surgery. Jun 18-21; Barcelona, Spain;
cars-int.org
FIME 2024 – Florida International Medical Expo.
Jun 19-21; Miami, FL, USA; fimeshow.com
ICEM 2024 – 22nd International Conference
on Emergency Medicine. Jun 19-23; Taipei.
Taiwan; ifem.cc

Medical Taiwan 2024. Jun 20-22; Taipei, Tai-
wan; medicaltaiwan.com.tw
ESICM EuroAsia 2024 – European Society of In-
tensive Care Medicine (ESICM) & Indian Society
of Critical Care Medicine (ISCCM). Jun 21-23;
Bengaluru, India; esicm.org
SIIM 2024 – Annual Meeting of the Society for
Imaging Informatics in Medicine. Jun 27-29;
National Harbor, MD, USA; siim.org
JULY
ESHRE 2024 – 40th Annual Meeting of the
European Society of Human Reproduction and
Embryology. Jul 7-10; Amsterdam, Nether-
lands; eshre.eu
Meditech 2024 – 8th International Health Fair.
Jul 9-12; Bogota, Colombia; feriameditech.com
Asia Health 2024. Jul 10-12; Bangkok, Thai-
land; medlabasia.com
SCCT 2024 – 19th Annual Scientific Meeting of
the Society of Cardiovascular Computed Tomog-
raphy. Jul 18-21; Washington, DC, USA; scct.org
IndoHealthCare 2024. Jul 31 - Aug 2; Jakarta,
Indonesia; indohealthcareexpo.com
AUGUST
38th Medicall Expo. Aug 2-4; Chennai, India;
medicall.in
APICS 2024 – Asia Pacific Intensive Care Sympo-
sium. Aug 17-19; Singapore; sg-apics.com
Expo Med – Hospitalar Mexico 2024. Aug 20-
22; Mexico City, Mexico; expomed.com.mx
Medical Fair China 2024. Aug 21-23; Shanghai,
China; medicalfair.cn
International Surgical Week 2024 – 50th World
Congress of the International Society of Surgery
ISS/SIC. Aug 25-29; Kuala Lumpur, Malaysia;
isw2024.org
ESC Congress 2024 - European Society of Cardi-
ology. Aug 30 - Sep 2; London, UK: escardio.org
SEPTEMBER
Medic East Africa 2024. Sep 4-6; Nairobi, Ken-
ya; www.mediceastafrica.com
ESRA 2024 – 41st Annual Congress of the Euro-
pean Society of Regional Anaesthesia and Pain
Therapy. Sep 4-7; Prague, Czech Republic;
esracongress.com
UAA 2024 – 21st Urological Association of Asia
Congress. Sep 5-8; Bali, Indonesia; uaanet.org
ERS International Congress 2024 – European
Respiratory Society. Sep 7-11; Vienna, Austria;
erscongress.org
EASD 2024 – 60th Annual Meeting of the Euro-
pean Association for the Study of Diabetes. Sep
9-13; Madrid, Spain; easd.org
47 World Hospital Congress of the International
Hospital Federation (IHF). Sep 10-12; Rio de
Janeiro, Brazil; ihf-fih.org
Medical Fair Asia 2024. Sep 11-13; Singapore;
medicalfair-asia.com
ASCI 2024 – The 17th Congress of Asian Society
of Cardiovascular Imaging. Sep 12-14; Shang-
hai, China; asci-heart.org
ESMO Congress 2024 - European Society for
Medical Oncology. Sep 13-17; Barcelona,
Spain; esmo.org
CIRSE 2024 – Annual Congress of the Cardiovas-
cular and Interventional Radiological Society of
Europe. Sep 14-18; Lisbon, Portugal; cirse.org
ISUOG World Congress 2024 – 34th World Con-
gress on Ultrasound in Obstetrics and Gynecol-
ogy. Sep 15-18; Budapest, Hungary; isuog.org
ISS 2024 Annual Meeting – International Skele-
tal Society. Sep 15-20; Montreal, QC, Canada;
internationalskeletalsociety.com
ExpoMedical 2024. Sep 18-20; Buenos Aires,
Argentina; expomedical.com.ar
20th EuGMS Congress – European Geriatric
Medicine Society. Sep 18-20; Valenica, Spain;
eugms2024.com
CBR24 – 53rd Congress of the Brazilian College
of Radiology and Diagnostic Imaging. Sep 19-
21 Salvador, Brazil; cbr.org.br
REHACARE 2024 – International Trade Fair for
Rehabilitation and Care. Sep 25-28; Dussel-
dorf, Germany; rehacare.com
CADI 2024 – Argentinian Congress of Diagnostic
Imaging. Sep 26-28; Buenos Aires, Argentina;
sar.org.ar
ASTRO 2024 – 66th Annual Scientific Meeting
of the American Society for Radiation Oncol-
ogy. Sep 29 – Oct 2; Washington, DC, USA;
astro.org
ACEP24 – Scientific Assembly of the American
College of Emergency Physicians. Sep 29 - Oct
2; Las Vegas, NV, USA; acep.org
OCTOBER
ESSO 43 – 43rd Congress of the European So-
ciety of Surgical Oncology. Oct 2-4; Antwerp,
Belgium; esso43.org
KCR 2024 – 80th Korean Congress of Radiology.
Oct 2-5; Seoul, Korea; kcr4u.org
EUSOBI 2024 - Annual Scientific Meeting of the
European Society of Breast Imaging. Oct 3-5;
Lisbon, Portugal; eusobi.org
JFR 2024 - Journées Francophones de Radiolo-
gie. Oct 4-7; Paris, France; www.jfr.plus
39th Medicall Expo. Oct 5-7; New Delhi, India;
medicall.in
ECISM LIVES 2024 – Annual Congress of Europe-
an Society of Intensive Care Medicine. Oct 5-9;
Barcelona, Spain; esicm.org
MICCAI 2024 – 27th International Conference
on Medical Image Computing and Computer
Assisted Intervention. Oct 6-10; Marrakesh,
Morocco; miccai.org
Medical Japan 2024 Tokyo– International Med-
ical and Elderly Care Expo. Oct 9-11; Tokyo,
Japan; medical-jpn.jp
UEG Week 2024 – United European Gastroen-
terology. Oct 12-15; Vienna, Austria; ueg.eu
CMEF Autumn 2024 – 90th China Medical
Equipment Fair. Oct 12-15; Shenzhen, China;
www.cmef.com.cn
EUSEM 2024 – 18th European Emergency
Medicine Congress. Oct 13-16; Copenhagen,
Denmark; eusemcongress.org
RANZCR 2024 – 74th Annual Scientific Meeting
of The Royal Australian and New Zealand Col-
lege of Radiologists. Oct 17-19; Perth, Austra-
lia; ranzcrasm.com
ANESTHESIOLOGY 2024 – Annual Meeting of
the American Society of Anesthesiologists. Oct
International
Calendar
18-22; Philadelphia, PA, USA; asahq.org
ACS Clinical Congress 2024 – American College
of Surgeons. Oct 19-22; San Francisco, CA,
USA; facs.org
EANM 2024 – 37th Annual Congress of the
European Association of Nuclear Medicine. Oct
19-23; Hamburg, Germany; eanm.org
Global Health Exhibition 2024. Oct 22-24; Ri-
yadh, Saudi Arabia; globalhealthsaudi.com
Africa Health 2024. Oct 22-24; Johannesburg,
South Africa; africahealthexhibition.com
16th World Stroke Congress - World Stroke
Organization. Oct 23-26; Abu Dhabi, UAE;
worldstrokecongress.org
NOVEMBER
APSR 2024 – 28th Congress of the Asian Pacific
Society of Respirology. Nov 7-10; Singapore;
apsr2024.hk
MEDICA 2024. Nov 11-14; Dusseldorf, Germa-
ny; medica-tradefair.com
CBMI 2024 – 29th Brazilian Congress of Inten-
sive Care Medicine. Nov 14-16; Sao Paulo,
Brazil; amib.org.br
ASUS 2024 – 7th Congress of Asian Surgical
Ultrasound Society. Nov 16-17; Seoul, Korea,
asus2024.org
DECEMBER
RSNA 2024 – Annual Meeting of the Radiologi-
cal Society of North America. Dec 1-5; Chicago,
IL, USA; rsna.org
66th ASH Annual Meeting and Exposition –
American Society of Hematology. Dec 7-10;
San Diego, CA, USA; hematology.org
2025
JANUARY
Arab Health 2025. Jan 27-30; Dubai, UAE;
arabhealthonline.com
FEBRUARY
Critical Care Congress 2025 – 54th Annual Meet-
ing of the Society of Critical Care Medicine (SC-
CM). Feb 23-25; Orlando, FL, USA; sccm.org

HospiMedica Vol. 42 Issue 1

Advertising Index
V I S I T
International 3/2024
LINKXPRESS COM
®

Inq.No. Advertiser Page

R E A D E R S E R V I C E P O R T A L

– ECR 2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Renew/Start Your
Free Subscription – ESC Congress 2024 . . . . . . . . . . . . . . . . . . . 13

Access Instant Online – Expomed Eurasia. . . . . . . . . . . . . . . . . . . . . . 15

Product Information – HospiMedica . . . . . . . . . . . . . . . . . . . . . . . . . 19

Every advertisement or product item – HospiMedica EXPO. . . . . . . . . . . . . . . . . . . . . 3

in this issue contains a LinkXpress number
as shown below: – IHF Rio 2024. . . . . . . . . . . . . . . . . . . . . . . . . 22
LINKXPRESS COM HMI-03-24 999
111 Lumiquick. . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Identify LinkXpress codes of
1 interest as you read magazine 105 Radcal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Click on LinkXpress.com
2 to reach reader service portal
124 Sekisui. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3 Mark code(s) of interest on
LinkXpress inquiry matrix
102 Singuway. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
ATTENTION: IF YOUR APPLICATION IS
NOT RECEIVED AT LEAST ONCE EVERY 12
117 Vicolab. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
MONTHS YOUR FREE SUBSCRIPTION MAY
BE AUTOMATICALLY DISCONTINUED 109 West Medica . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Provided as a service to advertisers. Publisher cannot accept responsibility for any errors or omissions.
 50% of time vaginitis
symptoms are misdiagnosed3
42% of women receive
Beverly inappropriate treatment2

40% of women leave the

medical visit undiagnosed1
Trixie

Are Vaginitis Disorders Underdiagnosed?

Beverly and Trixie can be very hard to diagnose which is why
the OSOM® Trichomonas and OSOM® BVBLUE® tests are a
valuable tool.
They offer non-invasive, point-of care testing with over
90% accuracy. Both products give accurate results within
10 minutes or less, with colour changing results allowing for quick,
easy interpretation.

Speed, Accuracy and Value. Awesome........yes, OSOM.

Visit us at osomtests.com

Click or scan the QR code to Click or scan the QR code to

watch our Webinar on Vaginitis access our Vaginosis article

LINKXPRESS COM HMI-03-24 124

1.Carr, P. “Shotgun” Versus Sequential Testing. J Gen Intern Med. 2005. 2. Hiller, S. Diagnosis and Treatment of Vaginal Discharge Syndromes in Community
Practice Settings. Clinical Infectious Disease. 2020. 3. Brown, H. Improving the Diagnosis of Vulvovaginitis. Population Health Management. Vol. 23, suppl 1, 2020.

© 2024 SEKISUI Diagnostics, LLC. All rights reserved. OSOM® and QC Inside® are registered trademark of SEKISUI Diagnostics, LLC. Because every result matters™
is a trademark of SEKISUI Diagnostics, LLC.